Influenza virus hemagglutinin mutants
By expressing the modified influenza virus hemagglutinin protein in plants to form VLP, the problems of insufficient yield and poor immunogenicity of the existing recombinant vaccine are solved, and more efficient influenza virus immunogenicity and yield are achieved.
Patent Information
- Application Number
- CN201980038609.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-06-27
- Filing Date
- 2019-06-27
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-06-27
AI Technical Summary
The existing recombinant influenza virus protein vaccines are insufficient in vitro expression systems and have poor immunogenicity, making it difficult to trigger a lasting protective immune response.
By introducing modified nucleic acid sequences in plants, the modified influenza virus hemagglutinin protein is expressed to form influenza virus-like microparticles (VLPs) to improve VLP yield and immunogenicity.
It improves the yield and immunogenicity of the influenza virus VLP, enhances the immune response to the influenza virus, and provides more effective vaccine candidates.
Smart Images

Figure CN112534056B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to producing mutant viral proteins in plants. More specifically, the present invention relates to producing influenza virus-like particles in plants and increasing the yield of influenza virus-like particles. Background Art
[0002] Influenza viruses are enveloped, single-stranded RNA viruses of the family Orthomyxoviridae. Influenza viruses are highly contagious and can cause mild to severe illness in all age groups.
[0003] Vaccination remains the most effective way to prevent influenza infection. Traditionally, vaccination is done using live attenuated viruses or fully inactivated viruses, which elicit an immune response when administered to a patient. To eliminate the potential risk of live attenuated viruses and fully inactivated viruses regaining the ability to replicate and infect, vaccines that include recombinant viral proteins are also used to elicit protective immunity against influenza infection.
[0004] However, the use of recombinant viral proteins as immunogenic components of vaccines is subject to a number of limitations. First, in the absence of a complete set of viral proteins and genetic components required for optimal expression and proper protein folding, the yield of recombinant viral proteins in standard in vitro expression systems may be insufficient for vaccine production purposes. Second, recombinant viral protein vaccines may exhibit poor immunogenicity due to improper folding, poor antigen presentation, and / or the generation of a primary humoral immune response that is ineffective in conferring durable protective immunity.
[0005] There are four types of influenza viruses: A, B, C and D, of which influenza A and B viruses are the causative organisms of seasonal epidemics of disease among humans.
[0006] Influenza A viruses are further divided based on the expression of hemagglutinin (HA) and neuraminidase (NA) glycoprotein subtypes on the viral surface. There are 18 different hemagglutinin subtypes (H1-H18).
[0007] Hemagglutinin is a trimeric lectin that promotes the binding of influenza virus particles to sialic acid-containing proteins on the surface of target cells and mediates the release of the viral genome into target cells. The hemagglutinin protein includes two structural elements: the head, which is the main target of serum protective antibodies; and the handle. Hemagglutinin is translated into a single polypeptide HA0 (assembled as a trimer), which must be cut between the HA1 (about 40kDa) subdomain and the HA2 (about 20kDa) subdomain by a serine endoprotease. After cleavage, the two disulfide-bonded protein domains adopt the necessary conformation required to achieve viral infectivity. HA1 forms a globular head domain including a receptor binding site (RBS) and is the least conserved fragment of influenza virus. HA2 is a unidirectional membrane-intrinsic protein with a fusion peptide (FP), a soluble extracellular domain (SE), a transmembrane domain (TM) and a cytoplasmic tail domain (CT), and the corresponding lengths of these domains are approximately 25, 160, 25 and 10 residues. HA2 together with the nitrogen- and carbon-terminal HA1 residues form the stalk domain, which includes the transmembrane domain and is relatively conserved.
[0008] Various mutations of influenza virus proteins, particularly the influenza virus hemagglutinin protein, have been studied.
[0009] For example, Castelán-Vega et al. (Adv Appl Bioinform Chem. 2014; 7: 37-44) used a stability prediction algorithm to compare 7479 full-length amino acid sequences of hemagglutinin from influenza A virus (H1N1) pdm09 and determined that the D104N, A259T, S124N, and E172K mutations resulted in predicted enhanced stability of the influenza virus hemagglutinin protein. In contrast, the S206T, K285E, and E47K mutations had a predicted destabilizing effect on the hemagglutinin.
[0010] In comparing the sequences of the original influenza A(H1N1) pdm [A / California / 7 / 2009] and a later emerging influenza strain [A / Brisbane / 10 / 2010], Cotter et al. (PLoS Pathog. 2014;10(1):e1003831) determined that the E47K mutation in the stalk domain of the A / California / 7 / 2009 hemagglutinin stabilizes the trimeric structure, lowers the pH for membrane fusion, and increases the heat and acid stability of the virus. Cotter et al. also observed that the A / California / 7 / 2009 E47K mutant hemagglutinin was more infectious in ferrets than its wild-type counterpart.
[0011] Antanasijevic et al. (J Biol Chem. 2014; 289(32): 22237-45) studied the structure-function properties of the stem-loop domain of H5 hemagglutinin by site-directed mutagenesis at 14 different positions. A / Vietnam / 1203 / 04 (H5N1) mutants were expressed in HEK 293T cells, and Antanasijevic reported that most mutations in the stem-loop domain did not disrupt expression, proteolytic processing, viral assembly, or receptor binding. However, Antanasijevic observed that the HA1-D26K, HA1-M102L, HA2-V52A, and HA2-I55A mutants (based on H3 numbering) exhibited significantly reduced levels of total hemagglutinin, suggesting reduced expression and / or assembly of hemagglutinin in viral particles. The HA1-D26K, HA2-T49A, and HA2-M102L mutants also exhibited lower hemagglutination titers compared to wild-type virus. Antanasijevic also observed that all single mutants had reduced ability to enter A549 pneumocytes, with the HA1-D26K and HA2-I55A mutants being the most impaired. Antanasijivec also demonstrated that the HA2-L99A mutant was more sensitive to inhibition of A549 pneumocytes by the C179 neutralizing antibody than the wild-type virus, suggesting that this mutation enhances the mode of antibody binding and / or neutralization. In contrast, the HA1-I28A, HA1-M31A, HA1-M31L, HA2-I45A, and HA2-I55V mutants were less sensitive to entry inhibition by the C179 neutralizing antibody.
[0012] WO2013 / 177444 by Lu et al. and its companion document (Proc Natl Acad Sci USA. 2014; 111(1): 125-30) report a method for producing a correctly folded hemagglutinin stem domain from A / California / 05 / 2009 (H1N1) using an E. coli-based cell-free protein expression system and a simple refolding protocol. To induce trimerization of the hemagglutinin stem domain, chloramphenicol acetyltransferase (CAT) or a folding domain was fused to the carbon terminus of the hemagglutinin. To mitigate newly exposed hydrophobicity and / or intermolecular ion pairing that leads to aggregation of the expressed hemagglutinin stem protein, five groups of mutations were evaluated: M1 (I69T+I72E+I74T+C77T); M2 (I69T+I72E+I74T+C77T+F164D); M3 (I69T+I72E+I74T+C77T+F164D+L174D); M4 (F164D); and M5 (F164D+L174D). Lu observed that the M5 (F164D+L174D) mutations appeared to have the greatest impact on improving the solubility of the hemagglutinin stem protein. Additional deletions (H38 to C43 and C49 to N61) and the C77T mutation were made to the M5 mutant to avoid the formation of undesirable disulfide bonds, reduce surface hydrophobicity and pI, and avoid regions with disordered structures.
[0013] Holtz et al. U.S. application 13 / 838,796 and its companion document (BMC Biotechnology. 2014; 14: 111) teach to improve the stability of recombinant hemagglutinin and maintain its effectiveness by mutation of cysteine residues in the carboxyl terminal domain of the hemagglutinin protein (including the transmembrane domain (TM) and the cytoplasmic domain (CT)). Specifically, Holtz et al. demonstrated C539A, C546A, C549A, C524S and C528A mutations in recombinant Perth / 16 / 2009 hemagglutinin (H3N2). Mutations of all five cysteine residues or their different subsets resulted in hemagglutinin yields, purity, particle size, hemagglutination activity and thermal stability comparable to recombinant wild-type hemagglutinin protein. In contrast, C64S and C76S mutations resulted in a significant reduction in hemagglutinin expression, which indicates the key role of these residues in the correct folding of hemagglutinin. By using a single radial immunodiffusion assay (SRID), Holtz et al. also showed that mutation of these five cysteine residues increased the potency of recombinant hemagglutinin by preventing disulfide cross-linking in the TM and CT domains compared to the wild-type protein. The mutant hemagglutinin protein maintained potency for at least 12 months at 25°C, whereas the wild-type hemagglutinin protein showed less than 40% potency after only 50 days after purification.
[0014] WO2015 / 020913 teaches mutation of specific residues at one or more positions selected from a group of positions 403, 406, 411, 422, 429, 432, 433 and 435 of influenza virus A / Puerto Rico / 8 / 1934 (H1N1) to tyrosine. These mutations promote the formation of dityrosine cross-links, thereby stabilizing or "locking" the handle domain of influenza virus hemagglutinin in its native trimeric conformation.
[0015] WO2013 / 079473 discloses a modified influenza virus hemagglutinin without a globular head domain. The polypeptide taught in WO2013 / 079473 includes an HA1 domain and an HA2 domain, wherein amino acids 53 to 620 (numbered with reference to A / Brisbane / 59 / 2007 [H1N1]) are deleted and replaced by a covalently linked sequence of 0 to 10 amino acids, wherein the carbon-terminal amino acid of the HA1 domain is an amino acid other than arginine or lysine, and wherein one or more amino acids at positions 406, 409, 413 and 416 are mutated to an amino acid selected from the group consisting of serine, threonine, asparagine, glutamine, arginine, histidine, lysine, aspartic acid, glutamic acid and glycine.
[0016] WO2014 / 191435 similarly teaches a modified influenza virus hemagglutinin comprising an HA1 domain and an HA2 domain, wherein a deleted segment of the HA1 domain is replaced by a covalently linked sequence of 0 to 50 amino acids, wherein the hemagglutinin resists cleavage at the junction of HA1 and HA2, and wherein one or more amino acids at positions 337, 340, 352, 353, 402, 406, 409, 413 and / or 416 have been mutated.
[0017] Virus-like particles (VLP) are potential candidates included in immunogenic compositions. VLP are very similar to mature virions, but they do not include viral genome material. Therefore, VLP is non-replicative in nature, which makes them safe as vaccine administration. In addition, VLP can be transformed into expressing viral glycoproteins on the surface of VLP, which is their most natural physiological structure. In addition, because VLP is similar to complete virions and is a multivalent particle structure, VLP may be more effective than soluble envelope protein antigens in inducing glycoprotein neutralizing antibodies.
[0018] VLPs have been produced in plants (see, for example, WO2009 / 076778; WO2009 / 009876; WO2009 / 076778; WO2010 / 003225; WO2010 / 003235; WO2010 / 006452; WO2011 / 03522; WO2010 / 148511 and WO2014153674, which are incorporated herein by reference).
[0019] WO2009 / 076778 teaches a method for producing influenza virus VLPs in plants, the method comprising introducing a nucleic acid having a regulatory domain active in plants, the regulatory domain operably linked to a nucleotide sequence encoding an influenza virus hemagglutinin from an influenza A or B virus.
[0020] WO2009 / 009876 teaches a method for producing influenza virus hemagglutinin VLPs in plants, wherein the influenza virus hemagglutinin self-assembles into VLPs in plant cells and in plant cell membrane buds.
[0021] WO2010 / 003225 discloses a method for producing influenza virus hemagglutinin VLPs in plants, the method comprising introducing a nucleic acid having a regulatory domain active in plants, the regulatory domain being operably linked to a nucleotide sequence encoding influenza virus hemagglutinin from A / California / 04 / 09 (H1N1).
[0022] WO2010 / 006452 teaches a method for producing VLPs comprising a modified influenza virus hemagglutinin protein, wherein the glycosylation sites at positions 154, 165, 286 or a combination thereof (referenced to A / Vietnam / 1194 / 04[H5N1] numbering) have been eliminated by mutating the residues at said positions to amino acids other than asparagine. WO2010 / 006452 also teaches that the amino acids at positions 156, 167, 288 or a combination thereof can be mutated to residues other than serine or threonine, thereby similarly eliminating the nitrogen-linked glycosylation signal triplet "NXS / T". By selectively deleting the glycosylation sites located in the globular head of the hemagglutinin protein, WO2010 / 006452 demonstrates that the resulting hemagglutinin protein has improved antigenicity and broader cross-reactivity.
[0023] WO2011 / 035422 teaches a method for preparing plant-derived VLPs, the method comprising: obtaining a plant or plant material comprising a VLP located within an apoplast; producing a protoplast / spheroplast fraction and an apoplast fraction; and recovering the apoplast fraction comprising the plant-derived VLPs.
[0024] WO2010 / 148511 discloses a method for producing influenza virus VLPs in plants, wherein the VLPs include a chimeric hemagglutinin protein. The chimeric hemagglutinin protein includes a stem domain cluster having F'1, F'2 and F subdomains; a head domain cluster having RB, E1 and E2 subdomains; and a transmembrane domain cluster having a transmembrane domain and a carbon-terminal tail domain, wherein at least one subdomain is derived from a first influenza virus strain, and the other subdomains are derived from one or more second influenza virus strains.
[0025] WO2014 / 153674 teaches a method for producing influenza virus VLPs in plants, wherein the VLPs include a modified influenza virus hemagglutinin with a modified proteolytic loop. The modified proteolytic loop includes a proteolytic cleavage site between the HA1 and HA2 domains of the HA0 precursor. Therefore, compared with the native hemagglutinin protein, the hemagglutinin protein is stabilized and the protein yield is increased. Summary of the invention
[0026] The present invention relates to producing modified influenza virus proteins in plants. More specifically, the present invention relates to producing influenza virus-like particles (VLPs) in plants and increasing the yield of influenza virus-like particles (VLPs), wherein the VLPs include modified influenza virus proteins, such as modified hemagglutinin (HA) proteins.
[0027] It is an object of the present invention to provide an improved method for increasing the production of influenza virus VLPs in plants.
[0028] According to the present invention, there is provided:
[0029] A. A nucleic acid comprising a nucleotide sequence encoding a modified H3 influenza virus hemagglutinin (HA) protein, wherein the hemagglutinin protein comprises an amino acid sequence comprising at least one substitution compared to the corresponding wild-type amino acid sequence, wherein the at least one substitution is located at one or more amino acids corresponding to the amino acid at position 382, 384, 392 or 431 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0030] The hemagglutinin protein may include an amino acid sequence having a non-asparagine substitution at an amino acid corresponding to the amino acid at position 382 of the A / Hong Kong / 4801 / 14 hemagglutinin. The hemagglutinin protein may include an amino acid sequence having an alanine substitution or a conservative alanine substitution at an amino acid corresponding to the amino acid at position 382 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0031] The hemagglutinin protein may include an amino acid sequence having a non-leucine substitution at an amino acid corresponding to the amino acid at position 384 of the A / Hong Kong / 4801 / 14 hemagglutinin. The hemagglutinin protein may include an amino acid sequence having a valine substitution or a conservative valine substitution at an amino acid corresponding to the amino acid at position 384 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0032] The hemagglutinin protein may include an amino acid sequence having a non-phenylalanine substitution at an amino acid corresponding to the amino acid at position 392 of the A / Hong Kong / 4801 / 14 hemagglutinin. The hemagglutinin protein may include an amino acid sequence having an aspartic acid substitution or a conservative aspartic acid substitution at an amino acid corresponding to the amino acid at position 392 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0033] The hemagglutinin protein may include an amino acid sequence having a non-leucine substitution at an amino acid corresponding to the amino acid at position 431 of the A / Hong Kong / 4801 / 14 hemagglutinin. The hemagglutinin protein may include an amino acid sequence having a methionine substitution or a conservative valine substitution at an amino acid corresponding to the amino acid at position 431 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0034] Also provided:
[0035] B. A nucleic acid comprising a nucleotide sequence encoding a modified H3 influenza virus hemagglutinin (HA) protein, wherein the hemagglutinin protein comprises an amino acid sequence comprising at least one substitution compared to the corresponding wild-type amino acid sequence, wherein the at least one substitution is located at one or more amino acids corresponding to the amino acid at position 382, 384, 392, 431, 524, 525, 526 or 528 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0036] The hemagglutinin protein may also include an amino acid sequence having a first non-asparagine substitution at the amino acid corresponding to the amino acid at position 382 of the A / Hong Kong / 4801 / 14 hemagglutinin, a second non-cysteine substitution at the amino acid corresponding to the amino acid at position 524 of the A / Hong Kong / 4801 / 14 hemagglutinin, and a third non-cysteine substitution at the amino acid corresponding to the amino acid at position 528 of the A / Hong Kong / 4801 / 14 hemagglutinin. The hemagglutinin protein may also include an amino acid sequence having a first alanine substitution or a conservative alanine substitution at the amino acid corresponding to the amino acid at position 382 of the A / Hong Kong / 4801 / 14 hemagglutinin, a second serine substitution or a conservative serine substitution at the amino acid corresponding to the amino acid at position 524 of the A / Hong Kong / 4801 / 14 hemagglutinin, and a third leucine substitution or a conservative leucine substitution at the amino acid corresponding to the amino acid at position 528 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0037] The hemagglutinin protein may also include an amino acid sequence having a first non-leucine substitution at an amino acid corresponding to the amino acid at position 384 of the A / Hong Kong / 4801 / 14 hemagglutinin, a second non-cysteine substitution at an amino acid corresponding to the amino acid at position 524 of the A / Hong Kong / 4801 / 14 hemagglutinin, and a third non-cysteine substitution at an amino acid corresponding to the amino acid at position 528 of the A / Hong Kong / 4801 / 14 hemagglutinin. The hemagglutinin protein may also include an amino acid sequence having a first valine substitution or a conservative valine substitution at an amino acid corresponding to the amino acid at position 384 of the A / Hong Kong / 4801 / 14 hemagglutinin, a second serine substitution or a conservative serine substitution at an amino acid corresponding to the amino acid at position 524 of the A / Hong Kong / 4801 / 14 hemagglutinin, and a third leucine substitution or a conservative leucine substitution at an amino acid corresponding to the amino acid at position 528 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0038] The hemagglutinin protein may also include an amino acid sequence having a first non-phenylalanine substitution at an amino acid corresponding to the amino acid at position 392 of the A / Hong Kong / 4801 / 14 hemagglutinin, a second non-cysteine substitution at an amino acid corresponding to the amino acid at position 524 of the A / Hong Kong / 4801 / 14 hemagglutinin, and a third non-cysteine substitution at an amino acid corresponding to the amino acid at position 528 of the A / Hong Kong / 4801 / 14 hemagglutinin. The hemagglutinin protein may also include an amino acid sequence having a first aspartic acid substitution or a conservative aspartic acid substitution at an amino acid corresponding to the amino acid at position 392 of the A / Hong Kong / 4801 / 14 hemagglutinin, a second serine substitution or a conservative serine substitution at an amino acid corresponding to the amino acid at position 524 of the A / Hong Kong / 4801 / 14 hemagglutinin, and a third leucine substitution or a conservative leucine substitution at an amino acid corresponding to the amino acid at position 528 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0039] The hemagglutinin protein may also include an amino acid sequence having a first non-leucine substitution at an amino acid corresponding to the amino acid at position 431 of the A / Hong Kong / 4801 / 14 hemagglutinin, a second non-cysteine substitution at an amino acid corresponding to the amino acid at position 524 of the A / Hong Kong / 4801 / 14 hemagglutinin, and a third non-cysteine substitution at an amino acid corresponding to the amino acid at position 528 of the A / Hong Kong / 4801 / 14 hemagglutinin. The hemagglutinin protein may also include an amino acid sequence having a first methionine substitution or a conservative methionine substitution at an amino acid corresponding to the amino acid at position 431 of the A / Hong Kong / 4801 / 14 hemagglutinin, a second serine substitution or a conservative serine substitution at an amino acid corresponding to the amino acid at position 524 of the A / Hong Kong / 4801 / 14 hemagglutinin, and a third leucine substitution or a conservative leucine substitution at an amino acid corresponding to the amino acid at position 528 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0040] The hemagglutinin protein may also include an amino acid sequence having a first non-asparagine substitution at the amino acid corresponding to the amino acid at position 382 of the A / Hong Kong / 4801 / 14 hemagglutinin, a second non-leucine substitution at the amino acid corresponding to the amino acid at position 384 of the A / Hong Kong / 4801 / 14 hemagglutinin, a third non-cysteine substitution at the amino acid corresponding to the amino acid at position 524 of the A / Hong Kong / 4801 / 14 hemagglutinin, and a fourth non-cysteine substitution at the amino acid corresponding to the amino acid at position 528 of the A / HongKong / 4801 / 14 hemagglutinin. The hemagglutinin protein may also include an amino acid sequence having a first alanine substitution or a conservative alanine substitution at the amino acid corresponding to the amino acid at position 382 of the A / Hong Kong / 4801 / 14 hemagglutinin, a second valine substitution or a conservative valine substitution at the amino acid corresponding to the amino acid at position 384 of the A / Hong Kong / 4801 / 14 hemagglutinin, a third serine substitution or a conservative serine substitution at the amino acid corresponding to the amino acid at position 524 of the A / Hong Kong / 4801 / 14 hemagglutinin, and a fourth leucine substitution or a conservative leucine substitution at the amino acid corresponding to the amino acid at position 528 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0041] The hemagglutinin protein may also include an amino acid sequence having a substitution at an amino acid corresponding to the amino acid at position 525 or 526 or 525 and 526 of the A / Hong Kong / 4801 / 14 hemagglutinin, wherein the amino acid substitution at position 525 is a non-phenylalanine substitution, and the amino acid substitution at position 526 is a non-leucine substitution. The hemagglutinin protein may also include an amino acid sequence having a substitution at an amino acid corresponding to the amino acid at position 525 or 526 or 525 and 526 of the A / Hong Kong / 4801 / 14 hemagglutinin, wherein the amino acid substitution at position 525 is a leucine substitution or a conservative leucine substitution, and the amino acid substitution at position 526 is a valine substitution or a conservative valine substitution.
[0042] Also provided is a hemagglutinin protein encoded by the recombinant nucleic acid described under item A or B above and a virus-like particle (VLP) comprising the hemagglutinin protein encoded by the recombinant nucleic acid described under item A or B above.
[0043] Therefore, a modified hemagglutinin (HA) protein is also provided, which modified hemagglutinin (HA) protein includes an amino acid sequence comprising at least one substitution compared to the corresponding wild-type amino acid sequence, wherein the at least one substitution is located at one or more amino acids corresponding to the amino acid at position 382, 384, 392 or 431 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0044] In another aspect, a modified H3 influenza virus hemagglutinin (HA) protein is provided, the hemagglutinin protein comprising an amino acid sequence comprising at least one substitution compared to the corresponding wild-type amino acid sequence, wherein the at least one substitution is located at one or more amino acids corresponding to the amino acid at position 382, 384, 392, 431, 524, 525, 526 or 528 of the A / Hong Kong / 4801 / 14 hemagglutinin.
[0045] In addition, a method for producing influenza virus-like particles (VLPs) in a plant, a plant part or a plant cell is provided, the method comprising:
[0046] a) introducing a recombinant nucleic acid as described under A or B above into a plant, plant part or plant cell; and
[0047] b) incubating the plant, plant part or plant cell under conditions that allow expression of the hemagglutinin protein encoded by the recombinant nucleic acid, thereby producing VLPs. The method may also include the step of harvesting the plant, plant part or plant cell and purifying the VLPs c).
[0048] Also provided is a method for producing influenza virus-like particles (VLPs) in a plant, plant part or plant cell, the method comprising:
[0049] a) providing a plant, plant part or plant cell comprising a recombinant nucleic acid as described under A or B above; and
[0050] b) incubating the plant, plant part or plant cell under conditions that allow expression of the hemagglutinin protein encoded by the recombinant nucleic acid, thereby producing VLPs. The method may also include the step of harvesting the plant, plant part or plant cell and purifying the VLPs c).
[0051] In addition, a method for increasing the yield of influenza virus-like particles (VLPs) in plants, plant parts or plant cells is provided, the method comprising: a) introducing the recombinant nucleic acid in item A or B above into a plant, plant part or plant cell; or providing a plant, plant part or plant cell comprising the recombinant nucleic acid in item A or B above; and b) incubating the plant, plant part or plant cell under conditions that allow the expression of the hemagglutinin protein encoded by the recombinant nucleic acid, thereby producing VLPs with a higher yield compared to plants, plant parts or plant cells expressing unmodified influenza virus hemagglutinin protein. The method may also include the step of harvesting the plant, plant part or plant cell and purifying the VLP c).
[0052] The method may further comprise introducing a second nucleic acid encoding a proton channel protein; wherein the plant, plant part or plant cell is cultivated under conditions allowing expression of the proton channel protein encoded by the second nucleic acid. The proton channel protein may be an influenza A virus M2 subtype protein.
[0053] Also provided is a VLP produced by the method described herein.
[0054] The VLP may include one or more lipids derived from plants, plant parts or plant cells, plant-specific N-glycans, modified N-glycans, or a combination thereof.
[0055] In addition, a method for producing an antibody or antibody fragment is also provided, the method comprising administering the VLP to a subject or a host animal, thereby producing the antibody or antibody fragment. An antibody or antibody fragment produced by the method is also provided.
[0056] In addition, a plant, plant part or plant cell comprising the recombinant nucleic acid of item A or B above or the hemagglutinin protein encoded by the recombinant nucleic acid of item A or B above is provided. The hemagglutinin protein can form VLP. Therefore, a plant, plant part or plant cell comprising VLP is also provided, and the VLP comprises the hemagglutinin protein encoded by the recombinant nucleic acid of item A or B above.
[0057] In addition, a composition for inducing an immune response is provided, the composition comprising an effective dose of VLP as described herein, and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient. A method for inducing immunity to influenza virus infection in a subject is also provided, the method comprising administering the VLP. The VLP can be administered to the subject orally, intranasally, intramuscularly, intraperitoneally, intravenously or subcutaneously.
[0058] In addition, a modified influenza virus hemagglutinin (HA) protein is provided, wherein the influenza virus hemagglutinin (HA) protein includes at least one substitution described herein and is capable of forming VLPs, inducing an immune response, inducing a hemagglutination reaction, or a combination thereof when administered to a subject, the influenza virus hemagglutinin (HA) protein includes an amino acid sequence having about 30% to about 100% sequence identity or sequence similarity to one of the sequences of SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 43, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 53, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, and SEQ ID NO: 98.
[0059] This summary does not necessarily describe all features of the invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0060] These and other features of the present invention will become more apparent from the following description given with reference to the accompanying drawings, in which:
[0061] Figure 1 A / Bangkok / 3007 / 15(H3N2)(SEQ ID NO:91); A / Hongkong / 4801 / 14(H3N2)(SEQ ID NO:92); A / Minnesota / 40 / 15(H3N2)(SEQ ID NO:93); A / South Sequence alignment of the amino acid sequences of hemagglutinin (HA) from Australia / 1 / 16(H3N2) (SEQ ID NO: 94); A / Pennsylvania / 09 / 15(H3N2) (SEQ ID NO: 95); A / Switzerland / 9715293 / 13(H3N2) (SEQ ID NO: 96); and A / Mississippi / 16 / 16(H3N2) (SEQ ID NO: 97); the listed residues are aligned with amino acids N382, L384, F392, and L431 of hemagglutinin from influenza virus H3 strain (H3N2), such as A / Hongkong / 4801 / 14(H3N2) (SEQ ID NO: 92).
[0062] Figure 2Hemagglutination titers of wild-type A / Switzerland / 9715293 / 13 H3, N382A A / Switzerland / 9715293 / 13 mutant H3, L384V A / Switzerland / 9715293 / 13 mutant H3, F392D A / Switzerland / 9715293 / 13 mutant H3 and L431M A / Switzerland / 9715293 / 13 mutant H3 are shown.
[0063] Figure 3 Hemagglutination titers of wild-type A / Indonesia / 5 / 2005 H5, wild-type A / Egypt / N04915 / 2014 H5, F393D A / Indonesia / 5 / 2005 mutant H5, F393D A / Egypt / N04915 / 2014 mutant H5, N383A A / Indonesia / 5 / 2005 mutant H5, and N383A A / Egypt / N04915 / 2014 mutant H5 are shown. Numbering is determined according to A / Indonesia / 5 / 2005.
[0064] Figure 4A A schematic diagram of vector 3045 (H3 A-Swi-9715293-13(F392D)) is shown. Figure 4B A schematic diagram of carrier 3022 (H3 A-Swi-9715293-13 (L431M)) is shown. Figure 4C A schematic diagram of vector 3023 (H3 A-Swi-9715293-13(N382A)) is shown. Figure 4D A schematic diagram of vector 3034 (H3 A-Swi-9715293-13 (L384V)) is shown.
[0065] Figure 5A A schematic diagram of vector 3556 (a vector used for fusion cloning into a CPMV 160-based expression cassette under the control of the alfalfa plastocyanin promoter and terminator in addition to the M2 accessory protein) is shown. Figure 5B A schematic diagram of vector 1190 (a vector used for fusion cloning into a CPMV 160-based expression cassette) is shown.
[0066] Fig. 6A Hemagglutination titers of wild-type A / Switzerland / 9715293 / 13 H3 and CysTM A / Switzerland / 9715293 / 13 mutant H3 are shown.
[0067] Figure 6BHemagglutination titers of wild-type A / Pennsylvania / 09 / 2015 H3 and Cys™ A / Pennsylvania / 09 / 2015 mutant H3 are shown.
[0068] Fig. 7A Wild-type A / Switzerland / 9715293 / 13 H3, N382A A / Switzerland / 9715293 / 13 mutant H3, L384V A / Switzerland / 9715293 / 13 mutant H3, F392D A / Switzerland / 9715293 / 13 mutant H3, L431M A / Switzerland / 9715293 / 13 mutant H3, A / Switzerland / 9715293 / 13 H3 with CysTM modification, N382A+CysTM A / Switzerland / 9715293 / 13 mutant H3, L384V+CysTM A / Switzerland / 9715293 / 13 mutant H3, F392D+CysTM Hemagglutination titers of A / Switzerland / 9715293 / 13 mutant H3 and L431M+CysTM A / Switzerland / 9715293 / 13 mutant H3. Figure 7B The post-density gradient VLP yields of CysTM A / Switzerland / 9715293 / 13 mutant H3, N382A+CysTM A / Switzerland / 9715293 / 13 mutant H3, L384V+CysTM A / Switzerland / 9715293 / 13 mutant H3, F392D+CysTM A / Switzerland / 9715293 / 13 mutant H3 and L431M+CysTM A / Switzerland / 9715293 / 13 mutant H3 are shown as a percentage of CysTM A / Switzerland / 9715293 / 13 mutant H3. Figure 7C Hemagglutination titers of wild-type A / Pennsylvania / 09 / 2015 H3, Cys™ A / Pennsylvania / 09 / 2015 mutant H3, N382A+Cys™ A / Pennsylvania / 09 / 2015 mutant H3, and L384V+Cys™ A / Pennsylvania / 09 / 2015 mutant H3 are shown. Fig.7DThe hemagglutination titers of Cys™ A / S.Australia / 1 / 16 mutant H3 and N382A+L384V+Cys™ A / S.Australia / 1 / 16 mutant H3 are shown. Fig. 7E CysTM A / Hong Kong / 4801 / 14 mutant H3 and N382A+L384V+CysTM A / HongKong / 4801 / 14 mutant H3; CysTM A / Minnesota / 40 / 15 mutant H3 and N382A+L384V+CysTM A / Minnesota / 40 / 15 mutant H3; CysTM A / S.Australia / 1 / 16 mutant H3 and N382A+L384V+CysTMA / S.Australia / 1 / 16 mutant H3; CysTM A / Bangkok / 3007 / 15 mutant H3 and N382A+L384V+CysTMA / Bangkok / 3007 / 15 mutant H3; CysTM Hemagglutination titers of A / Switzerland / 9715293 / 13 mutant H3 and L384V+CysTMA / Switzerland / 9715293 / 13 mutant H3; CysTM A / Mississippi / 16 / 16 mutant H3 and N382A+L384V+CysTM A / Mississippi / 16 / 16 mutant H3.
[0069] Fig. 8A A schematic diagram of carrier 3340 (H3 A-HK-4801-14) is shown. Figure 8B A schematic diagram of vector 3341 (H3 A-HK-4801-14) is shown. Figure 8C A schematic diagram of vector 3375 (H3 A-HK-4801-14 (N382A+L384V)) is shown. Fig.8D A schematic diagram of vector 3914 (H3 A-Minn-40-15) is shown. Fig. 8E A schematic diagram of vector 3915 (H3 A-Minn-40-15 (N382A+L384V)) is shown. Fig.8F A schematic diagram of vector 3924 (H3 A-SAus-1-16) is shown. Figure 8G A schematic diagram of vector 3925 (H3 A-SAus-1-16 (N382A+L384V)) is shown. Figure 8H A schematic diagram of vector 3904 (H3 A-Bang-3007-15) is shown. Figure 8IA schematic diagram of vector 3905 (H3 A-Bang-3007-15 (N382A+L384V)) is shown. Figure 8J A schematic diagram of vector 2801 (H3 A-Swi-9715293-13) is shown. Figure 8K A schematic diagram of vector 2811 (H3 A-Swi-9715293-13) is shown. Figure 8L A schematic diagram of vector 3063 (H3 A-Swi-9715293-13(N382A)) is shown. Figure 8M A schematic diagram of vector 3074 (H3 A-Swi-9715293-13 (L384V)) is shown. Figure 8N A schematic diagram of vector 3085 (H3 A-Swi-9715293-13(F392D)) is shown. Fig.8O A schematic diagram of vector 3062 (H3 A-Swi-9715293-13 (L431M)) is shown. Figure 8P A schematic diagram of vector 3312 (H3 A-Penn-09-15) is shown. Figure 8Q A schematic diagram of vector 3313 (H3 A-Penn-09-15) is shown. Figure 8R A schematic diagram of vector 3314 (H3 A-Penn-09-15 (N382A)) is shown. Figure 8S A schematic diagram of vector 3315 (H3 A-Penn-09-15 (L384V)) is shown.
[0070] Fig.9A A schematic diagram of vector 2295 (H5 A-Indo-5-05) is shown. Fig. 9B A schematic diagram of vector 3680 (H5 A-Indo-5-05 (F393D)) is shown. Fig. 9C A schematic diagram of vector 3645 (H5 A-Egypt-N04915-14) is shown. Fig.9D A schematic diagram of vector 3690 (H5 A-Egypt-N04915-14(F392D)) is shown. DETAILED DESCRIPTION
[0071] A preferred embodiment is described below.
[0072] The terms "comprising", "having", "including" and "containing" and their grammatical variations used herein are inclusive or open-ended and do not exclude other unlisted elements and / or method steps. When used in conjunction with a product, use or method in this article, the term "consisting essentially of..." indicates that additional elements and / or method steps may be present, but these added items do not substantially affect the mode of action of the method or use. When used in conjunction with a product, use or method in this article, the term "consisting of..." excludes the presence of additional elements and / or method steps. The products, uses or methods described herein that include certain elements and / or steps may also be composed essentially of these elements and / or steps in some embodiments, and of these elements and / or steps in other embodiments, regardless of whether these embodiments are specifically mentioned. In addition, unless otherwise stated, the use of the singular includes the plural, and "or" means "and / or". Unless otherwise defined herein, all technical and scientific terms used herein should be understood to have the meanings commonly understood by those of ordinary skill in the art. The term "approximately" used in this article refers to a difference of approximately + / -10% from a given value. It should be understood that such differences are always included in any given value provided herein, whether or not specifically mentioned. When used in conjunction with the term "comprising" herein, the use of the word "a" or "an" may mean "one", but also conforms to the meaning of "one or more", "at least one", and "one or more than one".
[0073] The terms "plant", "plant part", "plant part", "plant matter", "plant biomass", "plant material", "plant extract" or "plant leaf" as used herein may include complete plants, tissues, cells or any part thereof, intracellular plant components, extracellular plant components, liquid or solid extracts of plants, or combinations thereof that can provide transcription, translation and post-translational machinery for the expression of one or more nucleic acids described herein and / or from which the expressed proteins or VLPs can be extracted and purified. Plants may include, but are not limited to, herbaceous plants. In addition, plants may include, but are not limited to, crops, including rapeseed, Brassica plants, corn, Nicotiana plants (tobacco), etc., such as Nicotiana benthamiana, Nicotiana aurea, Nicotiana tabacum, Nicotiana safflower, Nicotiana solanaceae, Arabidopsis thaliana, alfalfa, potato, sweet potato (Ipomoea batatus), ginseng, pea, oat, rice, soybean, wheat, barley, sunflower, cotton, corn, rye (Secale cereale), sorghum (Sorghum bicolor, Sorghumvulgare), safflower (Carthamus tinctorius).
[0074] The term "plant part" as used herein refers to any part of a plant, including but not limited to leaves, stems, roots, flowers, fruits, plant cells obtained from leaves, stems, roots, flowers, fruits, plant extracts obtained from leaves, stems, roots, flowers, fruits, or combinations thereof. The term "plant extract" as used herein refers to plant-derived products obtained after physical treatment (e.g., freezing, then extracting in an appropriate buffer), mechanical treatment (e.g., grinding or homogenizing plants or plant parts, then extracting in an appropriate buffer), enzyme treatment (e.g., using cell wall degrading enzymes), chemical treatment (e.g., using one or more chelating agents or buffers), or combinations thereof. Plant extracts may also be processed to remove unwanted plant components, such as cell wall fragments. Plant extracts may be obtained to help reclaim one or more components from plants, plant parts, or plant cells, such as proteins (including protein complexes, protein superstructures, and / or VLPs), nucleic acids, lipids, carbohydrates, or combinations thereof from plants, plant parts, or plant cells. If the plant extract includes protein, it may be referred to as a protein extract. Protein extract can be a crude plant extract from plant tissue, a partially purified plant or protein extract, or a purified product comprising one or more proteins, protein complexes, protein superstructures and / or VLPs. If desired, protein extract or plant extract can be partially purified using technology well known to those skilled in the art, for example, extract can be subjected to salt or pH precipitation, centrifugal, gradient density centrifugation, filtration, chromatography, for example size exclusion chromatography, ion exchange chromatography, affinity chromatography or their combination. Also technology well known to those skilled in the art can be used to purify protein extract.
[0075] The terms "construct", "vector" or "expression vector" as used herein refer to a recombinant nucleic acid used to transfer an exogenous nucleic acid sequence into a host cell (e.g., a plant cell) and direct the expression of the exogenous nucleic acid sequence in the host cell. An "expression cassette" refers to a nucleotide sequence comprising a nucleic acid of interest, which is controlled by an appropriate promoter or other regulatory element responsible for the transcription of the nucleic acid of interest in the host cell and is operably linked to the promoter or other regulatory element. It will be appreciated by those skilled in the art that the expression cassette may include a termination (terminator) sequence, which is any sequence active in a plant host. For example, the termination sequence may be derived from the RNA-2 genomic fragment of a bipartite RNA virus (e.g., cowpea mosaic virus), the termination sequence may be a NOS terminator, or the terminator sequence may be obtained from the 3'UTR of the alfalfa plastocyanin gene.
[0076] The construct of the present disclosure may also include a 3' untranslated domain (UTR). The 3' untranslated domain contains polyadenylation signals and any other regulatory signals that can affect mRNA processing or gene expression. The polyadenylation signal is usually characterized by the addition of a polyadenylic acid track at the 3' end of the mRNA precursor. The polyadenylation signal is usually identified by homology with the standard form 5'AATAAA-3', of course, variations are not uncommon. Non-limiting examples of suitable 3' domains include a 3' transcribed untranslated domain that contains polyadenylation signals of Agrobacterium tumor-inducing (Ti) plasmid genes, such as nopaline synthase (Nos gene) and plant genes, such as soybean storage protein genes, small subunits of ribulose-1,5-bisphosphate carboxylase genes (ssRUBISCO; US4,962,028; the document is incorporated herein by reference), which is a promoter for regulating plastocyanin expression.
[0077] "Regulatory domain", "regulatory element" or "promoter" refers to a nucleic acid portion that is usually but not always upstream of the protein coding region of a gene, which can be composed of DNA or RNA, or composed of DNA and RNA. When the regulatory domain is active and operably associated or operably connected to the nucleotide sequence of interest, this may result in the expression of the nucleotide sequence of interest. The regulatory element can regulate organ specificity, or control development or temporal gene activation. "Regulatory domain" includes promoter elements, core promoter elements that exhibit basal promoter activity, elements that can be induced in response to external stimuli, and elements that regulate promoter activity, such as negative regulatory elements or transcription enhancers. "Regulatory domain" used herein also includes elements that are active after transcription, such as regulatory elements that regulate gene expression, such as translation and transcription enhancers, translation and transcription repressors, upstream activation sequences, and mRNA instability determinants. The latter several elements can be located near the coding region.
[0078] In the context of the present disclosure, the term "regulatory element" or "regulatory domain" generally refers to a DNA sequence that is usually, but not always, upstream (5') of the coding sequence of a structural gene, which controls the expression of the coding region by enabling recognition of RNA polymerase and / or other factors required to initiate transcription at a specific site. However, it should be understood that other nucleotide sequences located within the intragenic region or at the 3' end of the sequence may also help regulate the expression of the coding region of interest. An example of a regulatory element that enables recognition of RNA polymerase or other transcription factors to ensure initiation at a specific site is a promoter element. Most (but not all) eukaryotic promoter elements contain a TATA box, which is a conserved nucleic acid sequence consisting of adenosine and thymidine nucleotide base pairs that are usually located approximately 25 base pairs upstream of the transcription start site. Promoter elements may include basic promoter elements responsible for initiating transcription, as well as other regulatory elements that modify gene expression.
[0079] There are many types of regulatory domains, including developmentally regulated, inducible or constitutive regulatory domains. A regulatory domain that is developmentally regulated or controls differential expression of genes under its control is activated in a particular organ or tissue at a specific time during the development of that organ or tissue. However, some developmentally regulated regulatory domains may become preferentially active in certain organs or tissues at a specific developmental stage, they may also become active in a developmentally regulated manner, or remain active at a basal level in other organs or tissues within the plant. Examples of tissue-specific regulatory domains (e.g., seed-specific regulatory domains) include the Napin promoter and the Crucifer promoter (Rask et al., 1998, J. Plant Physiol. 152: 595-599; Bilodeau et al., 1994, Plant Cell 14: 125-130). An example of a leaf-specific promoter includes the plastocyanin promoter (see US 7,125,978, which is incorporated herein by reference).
[0080] Inducible regulatory domain is a domain that can directly or indirectly activate the transcription of one or more DNA sequences or genes in response to an inducer. In the absence of an inducer, the DNA sequence or gene will not be transcribed. Usually, the protein factor that specifically binds to the inducible regulatory domain to activate transcription can exist in an inactive form, and then the inducer is directly or indirectly converted into an active form. However, the protein factor may not exist. The inducer can be a chemical reagent, such as a protein, metabolite, growth regulator, herbicide or phenolic compound, or a physiological stress directly applied by heat, cold, salt or toxic elements or indirectly applied by the effect of pathogens or disease factors (such as viruses). By applying inducers (such as by spraying, watering, heating or similar methods) to cells or plants outside, plant cells comprising inducible regulatory domains can be exposed to inducers. Inducible regulatory elements can be derived from plants or non-plant genes (such as Gatz, C. and Lenk, IRP, 1998, Trends Plant Sci.3, 352-358). Examples of potential inducible promoters include, but are not limited to, tetracycline-inducible promoters (Gatz, C., 1997, Ann. Rev. Plant Physiol. Plant Mol. Biol. 48, 89-108), steroid-inducible promoters (Aoyama, T. and Chua, NH, 1997, Plant J. 2, 397-404) and ethanol-inducible promoters (Salter, MG et al., 1998, Plant Journal 16, 127-132; Caddick, MX et al., 1998, Nature Biotech. 16, 177-180), cytokinin-inducible IB6 and CKI1 genes (Brandstatter, I. and Kieber, JJ, 1998, Plant Cell 10, 1009-1019; Kakimoto, T., 1996, Science 274, 982-985), and the auxin-inducible element DR5 (Ulmasov, T. et al., 1997, Plant Cell 9, 1963-1971).
[0081] Constitutive regulatory domains direct gene expression in different parts of the plant and continue to be expressed during plant development. Examples of known constitutive regulatory elements include the promoter associated with the CaMV 35S transcript (p35S; Odell et al., 1985, Nature, 313:810-812; incorporated herein by reference), rice actin 1 (Zhang et al., 1991, Plant Cell, 3:1155-1165), actin 2 (An et al., 1996, Plant J., 10:107-121), or tms2 (U.S. Pat. No. 5,428,147), and the triosephosphate isomerase 1 (Xu et al., 1994, Plant Physiol. 106:459-467) gene, the maize ubiquitin 1 gene (Cornejo et al., 1993, Plant Mol. Biol. 29:637-646), the Arabidopsis thaliana ubiquitin 1 and 6 genes (Holtorf et al., 1995, Plant J. Biol. 29:637-646), and the rice tms2 (Tms2) (U.S. Pat. No. 5,428,147). Mol. Biol. 29: 637-646), tobacco translation initiation factor 4A gene (Mandel et al., 1995 Plant Mol. Biol. 29: 995-1004), cassava vein mosaic virus promoter pCAS (Verdaguer et al., 1996); promoter of ribulose bisphosphate carboxylase small subunit pRBCs (Outhkourov et al., 2003), pUbi (for monocots and dicots).
[0082] The term "constitutive" as used herein does not necessarily mean that a nucleotide sequence under the control of a constitutive regulatory domain is expressed at the same level in all cell types, but rather that the sequence is expressed in many cell types, even if variations in abundance are often observed.
[0083] The expression construct as described above may be present in a vector. The vector may include border sequences that allow the expression cassette to be transferred and integrated into the genome of an organism or host. The construct may be a plant binary vector, such as a binary transformation vector based on pPZP (Hajdukiewicz et al., 1994). Other exemplary constructs include pBin19 (see Frisch, DA, LW Harris-Haller et al., 1995, Plant Molecular Biology 27: 405-409).
[0084] The terms "native", "native protein" or "native domain" as used herein refer to a protein or domain having the same primary amino acid sequence as the wild type. A native protein or domain may be encoded by a nucleotide sequence having 100% sequence similarity to the wild type sequence. A native amino acid sequence may also be encoded by a human codon (hCod) optimized nucleotide sequence or a nucleotide sequence comprising an increased GC content compared to the wild type nucleotide sequence, provided that the amino acid sequence encoded by the HCoD-nucleotide sequence exhibits 100% sequence identity to the native amino acid sequence.
[0085] "Human codon optimized" nucleotide sequence or "hCod" nucleotide sequence refers to the selection of appropriate DNA nucleotides so that the synthesis of an oligonucleotide sequence or fragment thereof is close to the codon usage pattern commonly found in oligonucleotide sequences of human nucleotide sequences. "Increased GC content" refers to the selection of appropriate DNA nucleotides for the synthesis of an oligonucleotide sequence or fragment thereof to approach a codon usage pattern that includes an increased GC content (e.g., from about 1% to about 30%, or any amount between these values) over the length of the coding portion of the oligonucleotide sequence compared to the corresponding natural oligonucleotide sequence. For example, the GC content is about 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30%, or any amount between these values over the length of the coding portion of the oligonucleotide sequence. As described below, a human codon optimized nucleotide sequence or a nucleotide sequence comprising an increased GC content (compared to a wild-type nucleotide sequence) exhibits enhanced expression in a plant, plant part, or plant cell compared to expression of a non-human optimized (or lower GC content) nucleotide sequence.
[0086] A modified influenza virus hemagglutinin (HA) protein (also referred to as a modified HA protein, a modified influenza virus HA protein, a modified HA, a modified influenza virus HA, a mutant HA, an influenza virus mutant HA, an influenza virus HA variant, or an HA variant) and a method of producing a modified influenza virus hemagglutinin protein in a plant are described herein. The modified influenza virus hemagglutinin protein disclosed herein includes modifications or mutations that have been found to result in improved hemagglutinin properties compared to wild-type hemagglutinin or an unmodified hemagglutinin protein. For example, the modified influenza virus hemagglutinin protein can have an amino acid sequence with at least one amino acid substitution compared to the corresponding wild-type amino acid sequence.
[0087] Examples of improved properties of the modified hemagglutinin protein include: increased production of the hemagglutinin protein when expressed in plant cells compared to a wild-type or unmodified hemagglutinin of the same influenza strain or subtype that does not comprise the modification or mutation; improved hemagglutination titer of the modified hemagglutinin protein compared to a wild-type or unmodified hemagglutinin protein; improved integrity, stability, or integrity and stability of VLPs comprising the modified hemagglutinin protein compared to the integrity or stability, or integrity and stability, of VLPs comprising the modified hemagglutinin protein; increased production of VLPs when expressed in plant cells compared to the production of wild-type VLPs that do not comprise the modification or mutation; and combinations of these advantages.
[0088] Influenza virus subtypes and strains
[0089] The term "influenza virus subtype" as used herein refers to influenza A virus variants characterized by various combinations of hemagglutinin (H or HA) and neuraminidase (N) viral surface proteins. According to this specification, influenza virus subtypes and hemagglutinin (HA) from such virus subtypes may be referred to by their H numbers, such as "HA of H3 subtype", "H3HA" or "H3 influenza virus". The term "subtype" specifically includes all individual "strains" in each subtype, which are usually caused by mutations and may exhibit different pathogenic characteristics. Such strains may also be referred to as various "isolates" of virus subtypes. Therefore, the terms "strain" and "isolate" used herein may be used interchangeably.
[0090] Traditionally, different influenza strains are classified, for example, according to the ability of influenza virus to agglutinate red blood cells. Specific antibodies to a particular influenza virus strain can bind to the virus, thereby preventing this agglutination. Tests based on this inhibition to determine strain type are commonly referred to as hemagglutinin inhibition tests (HI tests or HAI tests), and are well-known standard methods for characterizing influenza strains in the art.
[0091] However, hemagglutinin proteins from different strains also show significant sequence similarity at the nucleic acid and amino acid levels. When comparing strains of different subtypes, it is found that the level of similarity varies, with some strains clearly showing higher levels of similarity than others (Air, Proc. Natl. Acad. Sci. USA, 1981, 78: 7643). The level of amino acid similarity varies between strains of different subtypes (Air, Proc. Natl. Acad. Sci. USA, 1981, 78: 7643). This variation is sufficient to determine the individual subtypes and evolutionary lineages of different strains, but the DNA and amino acid sequences of different strains are still easily compared using conventional bioinformatics techniques (Air, Proc. Natl. Acad. Sci. USA, 1981, 78: 7643; Suzuki and Nei, Mol. Biol. Evol. 2002, 19: 501).
[0092] Multiple nucleotide sequences or corresponding hemagglutinin polypeptide sequences can be aligned to determine a "common portion" or "consensus sequence" of a subtype (see Figure 1 ).
[0093] Based on sequence similarity, influenza virus subtypes can be further classified by reference to the phylogenetic groups of influenza virus subtypes. Phylogenetic analysis (Fouchier et al., J Virol. 2005 Mar; 79 (5): 2814-22) showed that hemagglutinin can be subdivided into two large groups (Air, Proc. Natl. Acad. Sci. USA, 1981, 78: 7643): i.e., H1, H2, H5 and H9 subtypes in phylogenetic group 1, and H3, H4 and H7 subtypes in phylogenetic group 2.
[0094] New influenza virus hemagglutinin proteins, hemagglutinin modifications, hemagglutinin protein variants and mutants are produced by changing the amino acid sequence of the hemagglutinin protein, which changes lead to improved hemagglutinin properties as described above. The isolation of nucleic acids encoding such hemagglutinin molecules is routine, and the modification of nucleic acids used to introduce changes in the amino acid sequence is also routine, such as by site-directed mutagenesis.
[0095] A modified influenza virus hemagglutinin protein and a method of producing the modified influenza virus hemagglutinin protein in a plant are described herein. It has been observed that modification (e.g., by substitution of specific amino acids in a hemagglutinin protein (e.g., a hemagglutinin from the H3 subtype)) results in improved properties of the modified hemagglutinin protein compared to a wild-type hemagglutinin protein or an unmodified hemagglutinin protein.
[0096] The one or more modifications, mutations or substitutions of the hemagglutinin protein described herein are not located in the globular head domain of the hemagglutinin protein, are not located in the known epitope region of the hemagglutinin protein, and these modifications, mutations or substitutions do not increase or remove glycosylation sites within the hemagglutinin protein.
[0097] The hemagglutinin protein, mutant hemagglutinin protein or modified hemagglutinin protein described herein is modified and has an amino acid sequence different from that of A / Hong Kong / 4801 / 14 (SEQ ID NO: 92; see Figure 1 )'s amino acid sequence comprises one or more mutations, modifications or substitutions at any one or more amino acids at positions 382, 384, 392, 431, 524, 525, 526, 527 or 528 of the amino acid sequence of the present invention.
[0098] "Corresponding to an amino acid" or "corresponding to an amino acid" means that one amino acid corresponds to another amino acid in a sequence alignment with a reference strain of influenza virus as described below.
[0099] The amino acid residue numbers or residue positions of the hemagglutinin are consistent with the numbering of the hemagglutinin of a reference influenza virus strain. For example, in the case of H3 influenza virus, the reference strain may be A / Hong Kong / 4801 / 14 [SEQ ID NO: 92; see Figure 1 The corresponding amino acid positions can be determined by aligning the sequence of a hemagglutinin (eg, H3 hemagglutinin) with the sequence of a hemagglutinin of a corresponding reference strain. Methods of sequence alignment for comparison are well known in the art. Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith and Waterman, Adv. Appl. Math. 2: 482 (1981), by the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48: 443 (1970), by the similarity search method of Pearson and Lipman, Proc. Nat'l. Acad. Sci. USA 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics software package, Genetics Computer Group, 575 Science Park, Madison, Wisconsin, USA), or by manual alignment and visual inspection (see, for example, Ausubel et al., 1995 Supplement to Molecular Biology). Figure 1 The amino acid sequence alignment of multiple influenza A virus hemagglutinin domains is shown in , and these examples should not be considered limiting.
[0100] When referring to a modification, mutant or variant, the wild-type amino acid residue (also referred to as "amino acid") is followed by the residue number and the new or substituted amino acid. For example, an asparagine (N, Asn) substitution residue or amino acid at position 382, alanine (A, Ala) is designated N382A (see Table 1).
[0101] Modified hemagglutinins, hemagglutinin mutants or variants (e.g., modified H3 hemagglutinins) are named in the same manner by using the single-letter amino acid code of the wild-type residue followed by the single-letter amino acid code of its position and the replacement residue. Multiple mutants are represented by individual component single mutants separated by slashes ( / ) or plus signs (+). Mutations or modifications in transmembrane (TM) domains or regions are represented as (CysTM). Thus, for example, H3 hemagglutinin mutant N382A+L384V (CysTM) is a mutant in which alanine (A, Ala) replaces asparagine (N, Asp) at residue position 382, valine (V, Val) replaces leucine (L, Leu) at residue position 384, and the H3 hemagglutinin mutant also has a mutation in the transmembrane domain.
[0102] Table 1. Positions of modifications in hemagglutinin and corresponding amino acid / residue positions in H3 and H5 influenza reference strains. Exemplary modifications are shown in brackets.
[0103]
[0104] 1 A / Hong Kong / 4801 / 14
[0105] 2 A / Indonesia / 05 / 05
[0106] The modified influenza virus hemagglutinin (HA) protein may include an amino acid sequence having at least one amino acid substitution compared to the corresponding wild-type amino acid sequence.
[0107] "Amino acid substitution" or "substitution" refers to the replacement of an amino acid in the amino acid sequence of a protein with a different amino acid. The terms "amino acid", "amino acid residue" or "residue" are used interchangeably in this disclosure. One or more amino acids can be replaced by one or more amino acids different from the original or wild-type amino acid at that position without changing the overall length of the amino acid sequence of the protein. Such substitutions or replacements can be experimentally induced by changing the codon sequence encoding the protein in the nucleotide sequence to a codon sequence for an amino acid different from the original or wild-type amino acid. The resulting protein is a modified protein, such as a modified influenza virus hemagglutinin protein. The modified influenza hemagglutinin protein does not occur naturally.
[0108] The modified hemagglutinin includes a non-naturally occurring hemagglutinin protein having at least one modification to a naturally occurring hemagglutinin and having improved properties compared to the naturally occurring hemagglutinin protein from which the amino acid sequence of the modified hemagglutinin is derived. The modified hemagglutinin protein has an amino acid sequence not found in nature, which is derived by replacing one or more amino acid residues of the hemagglutinin protein with one or more different amino acids.
[0109] Thus, a modified hemagglutinin, mutant hemagglutinin, or recombinant hemagglutinin refers to a hemagglutinin in which a DNA sequence encoding a naturally occurring hemagglutinin is modified to produce a modified or mutated DNA sequence encoding a modification, mutation, or substitution of one or more amino acids in the hemagglutinin amino acid sequence.
[0110] Some of the residues identified for modification, mutation or substitution correspond to conserved residues, while others do not. In the case of non-conserved residues, substitution of one or more amino acids is limited to substitutions that result in a modified hemagglutinin having an amino acid sequence that does not correspond to an amino acid sequence found in nature. In the case of conserved residues, such modification, substitution or replacement should also not result in a naturally occurring hemagglutinin sequence.
[0111] Conservative substitution
[0112] As described herein, residues in the hemagglutinin protein can be identified and modified, substituted or mutated to produce a modified hemagglutinin protein or a hemagglutinin protein variant. The substitution or mutation at a specific position is not limited to the amino acid substitutions described herein or given in the examples. For example, a hemagglutinin variant may comprise a conservative substitution of the amino acid substitutions.
[0113] As used herein, the term "conservative substitution" and its grammatical variations refer to the presence of an amino acid residue in the sequence of the hemagglutinin protein that is different from the substitution or residue but belongs to the same class of amino acids (i.e., a non-polar residue replacing a non-polar residue, an aromatic residue replacing an aromatic residue, a polar uncharged residue replacing a polar uncharged residue, a charged residue replacing a charged residue). In addition, conservative substitutions may encompass residues having an interfacial hydrophilicity value of the same sign and approximately similar magnitude as the residue replacing the wild-type residue.
[0114] As used herein, the term "non-polar residue" refers to glycine (G, Gly), alanine (A, Ala), valine (V, Val), leucine (L, Leu), isoleucine (I, Ile) and proline (P, Pro); the term "aromatic residue" refers to phenylalanine (F, Phe), tyrosine (Y, Tyr) and tryptophan (W, Trp); the term "polar uncharged residue" refers to serine (S, Ser), threonine (T, Thr), cysteine (C, Cys), methionine (M, Met), asparagine (N, Asn) and glutamine (Q, Gln); the term "charged residue" refers to the negatively charged amino acids aspartic acid (D, Asp) and glutamic acid (E, Glu), and the positively charged amino acids lysine (K, Lys), arginine (R, Arg) and histidine (H, His). Other classifications of amino acids are as follows:
[0115] Amino acids with hydrophobic side chains (aliphatic): alanine (A, Ala), isoleucine (I, Ile), leucine (L, Leu), methionine (M, Met), and valine (V, Val);
[0116] Amino acids with hydrophobic side chains (aromatic): phenylalanine (F, Phe), tryptophan (W, Trp), tyrosine (Y, Tyr);
[0117] Amino acids with polar neutral side chains: asparagine (N, Asn), cysteine (C, Cys), glutamine (Q, Gln), serine (S, Ser), and threonine (T, Thr);
[0118] Amino acids with charged side chains (acidic): aspartic acid (D, Asp), glutamic acid (E, Glu);
[0119] • Amino acids with charged side chains (basic): arginine (R, Arg); histidine (H, His); lysine (K, Lys), glycine (G, Gly) and proline (P, Pro).
[0120] Conservative amino acid substitutions may have similar effects on the activity of the resulting hemagglutinin protein variant or modified hemagglutinin protein as the original substitution or modification. More information about conservative substitutions can be found, for example, in papers by Ben Bassat et al. (J. Bacteriol, 169: 751-757, 1987), O'Regan et al. (Gene, 77: 237-251, 1989), Sahin-Toth et al. (Protein ScL, 3: 240-247, 1994), Hochuli et al. (Bio / Technology, 6: 1321-1325, 1988), and in widely used genetics and molecular biology textbooks.
[0121] The Blosum matrix is often used to determine the relatedness of polypeptide sequences. The Blosum matrix is created using a large trusted comparison database (BLOCKS database), which takes into account the alignment of paired sequences whose correlation is lower than a certain identity threshold percentage (Henikoff et al., Proc. Natl. Acad. Sci. USA, 89: 10915-10919, 1992). For the highly conservative target frequencies of the BLOSUM90 matrix, a 90% identity threshold is used. For the BLOSUM65 matrix, a 65% identity threshold is used. Scores above zero in the Blosum matrix are considered to be "conservative substitutions" at the selected percentage identity. Table 2 below shows exemplary conservative amino acid substitutions.
[0122] Table 2. Exemplary conservative amino acid substitutions
[0123]
[0124] The nucleotide sequence encoding the modified hemagglutinin protein can be optimized for human codon usage, increased GC content, or a combination thereof. The modified hemagglutinin protein can be expressed in a plant, plant part, or plant cell.
[0125] A. H3 hemagglutinin substitution I
[0126] A modified H3 influenza virus hemagglutinin protein and a method of producing the modified H3 influenza virus hemagglutinin protein in plants are described herein. It has been observed that modification of specific amino acids in a hemagglutinin protein from an H3 subtype results in improved properties of the modified H3 hemagglutinin protein compared to a wild-type H3 hemagglutinin protein or an unmodified H3 hemagglutinin protein.
[0127] In order to improve the properties of the H3 hemagglutinin protein, a total of 33 single substitutions, double modifications and / or triple modifications of residues that are not part of the transmembrane (TM) domain and cytoplasmic (CT) domain of the hemagglutinin and / or modifications of residues that are part of the transmembrane (TM) domain and cytoplasmic (CT) domain of the hemagglutinin were tested. As described herein and shown in the examples, only modifications or combinations of modifications at specific positions improved the properties of the H3 hemagglutinin protein. Modifications at 13 positions or combinations of these positions had adverse effects on the properties of the H3 hemagglutinin protein (data not shown).
[0128] Examples of improved properties of H3 hemagglutinin mutant proteins or modified H3 hemagglutinin proteins include: increased production or accumulation of hemagglutinin protein when expressed in plant cells compared to wild-type or unmodified hemagglutinin of the same influenza strain or subtype that does not include the modification or mutation; increased hemagglutination titer of the modified or mutated hemagglutinin protein compared to the wild-type or unmodified hemagglutinin protein; improved integrity, stability, or integrity and stability of VLPs comprising the modified hemagglutinin protein compared to the integrity or stability, or integrity and stability, of VLPs comprising the modified hemagglutinin protein; increased production of VLPs when expressed in plant cells compared to the production of wild-type VLPs that do not include the modification or mutation; and combinations of these advantages.
[0129] The modified H3 hemagglutinin protein or mutant H3 hemagglutinin protein described herein is modified and is compared with the reference strain A / Hong Kong / 4801 / 14 hemagglutinin (SEQ ID NO: 92; see Figure 1 ) comprises one or more mutations or modifications at any one or more residues in the sequence alignment of positions 382, 384, 392 and / or 431. Thus, an H3 influenza virus hemagglutinin polypeptide, protein and / or protein complex, such as a virus-like particle (VLP), is provided, the VLP comprising a modification or mutation at one or more of amino acid positions 382, 384, 392 and 431 (such amino acid numbering is based on the example of Figure 1 The sequence of A / Hong Kong / 4801 / 14 shown in Figure 92) may include a modification or mutation at an amino acid position corresponding to such an amino acid position, as determined, for example, by alignment of the hemagglutinin amino acid sequence with SEQ ID NO: 92. Non-limiting examples of H3 influenza virus hemagglutinin amino acid sequences that include one or more such mutations include SEQ ID NOs: 91, 92, 93, 94, 95, 96, and 97.
[0130] The modified H3 hemagglutinin proteins described herein include H3 hemagglutinin proteins having an amino acid sequence that has about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% sequence identity or sequence similarity, or any amount in between, to the amino acid sequence encoding the hemagglutinin from H3 (SEQ ID NOs: 91-97), wherein the amino acid sequence has one or more mutations or modifications at any one or more residues corresponding to positions 382, 384, 392, and 431 of the A / Hong Kong / 4801 / 14 hemagglutinin (SEQ ID NO: 92).
[0131] In addition, the H3 hemagglutinin protein can be encoded by a nucleotide sequence having a sequence identity or sequence similarity of about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100%, or any amount in between, to a nucleotide sequence encoding a hemagglutinin from H3 (SEQ ID NOs: 91-97), wherein the H3 hemagglutinin protein has one or more mutations or modifications at any one or more residues corresponding to positions 382, 384, 392, and 431 of the hemagglutinin of A / Hong Kong / 4801 / 14 (SEQ ID NO: 92), and wherein the nucleotide sequence encodes a hemagglutinin protein that forms VLPs when expressed.
[0132] Non-limiting examples of strains from which H3 hemagglutinins can be derived include A / Bangkok / 3007 / 15(H3N2) (SEQ ID NO: 91); A / Hongkong / 4801 / 14(H3N2) (SEQ ID NO: 92); A / Minnesota / 40 / 15(H3N2) (SEQ ID NO: 93); A / South Australia / 1 / 16(H3N2) (SEQ ID NO: 94); A / Pennsylvania / 09 / 15(H3N2) (SEQ ID NO: 95); A / Switzerland / 9715293 / 13(H3N2) (SEQ ID NO: 96) and A / Mississippi / 16 / 16(H3N2) (SEQ ID NO: 97).
[0133] Modification at position 382
[0134] In one aspect, an H3 hemagglutinin is provided, which may have a modified residue at position 382 (numbered according to A / Hong Kong / 4801 / 14 hemagglutinin numbering, SEQ ID NO: 92).
[0135] Antanasijevic et al. (J Biol Chem. 2014; 289(32): 22237-45) studied the structure-function properties of the stem-loop domain of H5 hemagglutinin by site-directed mutagenesis at 14 different positions. 41 , Gln 42 ,Ile 45 、Asn 53 and Leu 99 are highly conserved and were used to test the importance of these residues for hemagglutinin function. Antanasijevic noted that conservative mutations at positions HA1-I28V, HA2-T41A, HA2-T49A, HA2-N53A, and HA2-D57E abolished viral entry. In the case of the mutational effects on entry inhibition produced by the small molecule MBX2329, the outer surface HA2-Ile 45 HA2-Val 52 HA2-Asn 53 and HA2-Ser 54 and HA2-Leu on the inner surface 99 Substitution of has the greatest impact. These residues are highly conserved in family 1 hemagglutinins (e.g., H1 and H5). Position 53 in the H5 hemagglutinin of Antanasijevic corresponds to position 380 in the H1 hemagglutinin of the present disclosure and position 382 in the H3 hemagglutinin.
[0136] Unexpectedly, it was found that modification of the conserved residue at position 380 in the H1 hemagglutinin from asparagine to alanine resulted in an approximately 80% decrease in the hemagglutination titer of the modified H1 hemagglutinin compared to the wild-type H1 hemagglutinin (data not shown). However, the equivalent modification in the hemagglutinin from H5 also resulted in a decrease in the hemagglutination titer (see Figure 3 , Table 7). However, modification of the equivalent position in the hemagglutinin from H3(N382A) from asparagine to alanine resulted in an approximately 130% increase in hemagglutination titer compared to wild-type H3 hemagglutinin (see Figure 2 , Table 5).
[0137] Thus, the residue at position 382 of H3 hemagglutinin can be modified to a non-asparagine. For example, the residue at position 382 can be modified to a hydrophobic amino acid, such as alanine or a conservative alanine substitution, such as serine (S, Ser), glycine (G, Gly), threonine (T, Thr), cysteine (C, Cys) or valine (V, Val).
[0138] For example, the modified H3 hemagglutinin protein may have an amino acid sequence having about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the amino acid sequence of the hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 92), wherein the amino acid sequence has an alanine (A, Ala) or a conservative alanine (A, Ala) substitution at position 382, and wherein the sequence is not naturally occurring. The conservative alanine substitution may be, for example, serine (S, Ser), glycine (G, Gly), threonine (T, Thr), cysteine (C, Cys) or valine (V, Val).
[0139] The present specification also provides a nucleic acid comprising a nucleotide sequence encoding a modified H3 hemagglutinin having a substitution at position 382 as described above and operably linked to a regulatory domain active in plants.
[0140] For example, the nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the nucleotide sequence encoding the hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 102), wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having an alanine (A, Ala) or conservative alanine (A, Ala) substitution at position 382, and wherein the sequence is not naturally occurring. The conservative substitution may be, for example, serine (S, Ser), glycine (G, Gly), threonine (T, Thr), cysteine (C, Cys) or valine (V, Val).
[0141] The nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the nucleotide sequence of SEQ ID NO: 102, wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having an alanine (A, Ala) or conservative alanine (A, Ala) substitution at position 382, and wherein the sequence is not naturally occurring. The conservative substitution may be, for example, serine (S, Ser), glycine (G, Gly), threonine (T, Thr), cysteine (C, Cys) or valine (V, Val).
[0142] In addition to the residue at position 382, residues at positions 384, 524, 525, 526, 527, 528, or any combination thereof, may also be modified in the H3 hemagglutinin.
[0143] In addition, a method of producing VLPs in plants is provided, the VLPs comprising a modified H3 hemagglutinin having a substitution at least at position 382 and optionally at positions 384, 524, 525, 526, 527, 528, or any combination thereof. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0144] In addition, a method for increasing the yield of VLPs in plants is provided, the VLPs comprising a modified H3 hemagglutinin having a substitution at least at position 382 and optionally at positions 384, 524, 525, 526, 527, 528, or any combination thereof. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0145] The present specification also provides a VLP, which includes an H3 hemagglutinin having a substitution at least at position 382 and optionally at positions 384, 524, 525, 526, 527, and 528. The VLP can be produced by the method provided by the present specification. Compared with a VLP including an unmodified H3 hemagglutinin protein, the VLP protein including the modified H3 hemagglutinin shows improved properties.
[0146] Modification at position 384
[0147] In another aspect, an H3 hemagglutinin is provided, which may have a modified residue at position 384 (A / Hong Kong / 4801 / 14 hemagglutinin numbering, SEQ ID NO: 92).
[0148] For example, Figure 2 As shown in Table 5, modification of the residue at position 384 from leucine to valine resulted in an approximately 200% increase in hemagglutination titer compared to wild-type H3 hemagglutinin.
[0149] Thus, the residue at position 384 of H3 hemagglutinin can be modified to a non-leucine residue. For example, the residue at position 384 can be modified to valine or a conservative valine substitution other than leucine, such as isoleucine, methionine, alanine or threonine.
[0150] For example, the modified H3 hemagglutinin protein may have an amino acid sequence having about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the amino acid sequence of the hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 92), wherein the amino acid sequence has a valine (V, Val) or a conservative valine substitution other than leucine at position 384, wherein the sequence is not naturally present, and wherein the hemagglutinin protein forms VLPs when expressed. The conservative valine substitution may be, for example, isoleucine, methionine, alanine or threonine.
[0151] The present specification also provides a nucleic acid comprising a nucleotide sequence encoding a modified H3 hemagglutinin having a substitution at position 384 as described above and operably linked to a regulatory domain active in plants.
[0152] For example, the nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity therebetween with a nucleotide sequence encoding a hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 102), wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having a valine (V, Val) or a conservative valine (V, Val) substitution other than leucine at position 384, wherein the sequence is not naturally present, and wherein the nucleotide sequence encodes a hemagglutinin protein that forms VLPs when expressed. The conservative valine substitution may be, for example, isoleucine, methionine, alanine or threonine.
[0153] The nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity therebetween with the nucleotide sequence of SEQ ID NO: 102, wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having a valine (V, Val) or a conservative valine (V, Val) substitution other than leucine at position 384, wherein the sequence is not naturally present, and wherein the nucleotide sequence encodes a hemagglutinin protein that forms VLPs when expressed. The conservative valine substitution may be, for example, isoleucine, methionine, alanine or threonine.
[0154] In addition to the residue at position 384, residues at positions 382, 524, 525, 526, 527, 528, or any combination thereof, may also be modified in the H3 hemagglutinin.
[0155] In addition, a method of producing VLPs in plants is provided, the VLPs comprising a modified H3 hemagglutinin having a substitution at least at position 384 and optionally at positions 382, 524, 525, 526, 527, 528, or any combination thereof. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0156] In addition, a method for increasing the yield of VLPs in plants is provided, as described above, the VLPs comprising a modified H3 hemagglutinin having a substitution at least at position 384 and optionally at positions 382, 524, 525, 526, 527, 528 or any combination thereof. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0157] The present specification also provides a VLP, which includes an H3 hemagglutinin having a substitution at least at position 384 and optionally at positions 382, 524, 525, 526, 527, and 528. The VLP can be produced by the method provided by the present specification. Compared with a VLP including an unmodified H3 hemagglutinin protein, the VLP protein including the modified H3 hemagglutinin shows improved properties.
[0158] Modification at position 392
[0159] In another aspect, an H3 hemagglutinin is provided, which may have a modified residue at position 392 (H3 A / Hong Kong / 4801 / 14 hemagglutinin numbering, SEQ ID NO: 92).
[0160] For example, Figure 2 As shown in Table 5, modification of the residue at position 392 from phenylalanine to aspartic acid resulted in an approximately 140% increase in hemagglutination titer compared to wild-type H3 hemagglutinin.
[0161] Thus, the residue at position 392 of H3 hemagglutinin can be modified to a non-phenylalanine. For example, the residue at position 392 can be modified to an aspartic acid or a conservative aspartic acid substitution, such as glutamic acid, asparagine, glutamine or serine.
[0162] For example, the modified H3 hemagglutinin protein may have an amino acid sequence having about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the amino acid sequence of the hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 92), wherein the amino acid sequence has an aspartic acid or a conservative aspartic acid substitution, such as glutamic acid, asparagine, glutamine or serine, at position 392, wherein the sequence is not naturally present, and wherein the hemagglutinin protein forms VLPs when expressed. The conservative aspartic acid substitution may be, for example, glutamic acid, asparagine, glutamine or serine.
[0163] The present specification also provides a nucleic acid comprising a nucleotide sequence encoding a modified H3 hemagglutinin having a substitution at position 392 as described above and operably linked to a regulatory domain active in plants.
[0164] For example, the nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity therebetween with a nucleotide sequence encoding a hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 102), wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having an aspartic acid or conservative aspartic acid substitution at position 392, wherein the sequence is not naturally present, and wherein the nucleotide sequence encodes a hemagglutinin protein that forms a VLP when expressed. The conservative aspartic acid substitution may be, for example, glutamic acid, asparagine, glutamine or serine.
[0165] The nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity thereto with the nucleotide sequence of SEQ ID NO: 102, wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having an aspartic acid or a conservative aspartic acid substitution at position 392, wherein the sequence is not naturally present, and wherein the nucleotide sequence encodes a hemagglutinin protein that forms a VLP when expressed. The conservative aspartic acid substitution may be, for example, glutamic acid, asparagine, glutamine or serine.
[0166] In addition, a method of producing VLPs in a plant is provided, the VLPs comprising a modified H3 hemagglutinin as described above having a substitution at position 392. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0167] In addition, a method for increasing the yield of VLPs in a plant is provided, the VLPs comprising a modified H3 hemagglutinin as described above having a substitution at least at position 392. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0168] The present specification also provides a VLP comprising a H3 hemagglutinin having a substitution at least at position 392. The VLP can be produced by the method provided in the present specification. Compared with a VLP comprising an unmodified H3 hemagglutinin protein, the VLP protein comprising the modified H3 hemagglutinin exhibits improved properties.
[0169] Modification at position 431
[0170] In another aspect, an H3 hemagglutinin is provided, which may have a modified residue at position 431 (H3 A / Hong Kong / 4801 / 14 hemagglutinin numbering, SEQ ID NO: 92).
[0171] For example, Figure 2 As shown in Table 5, modification of the residue at position 431 from leucine to methionine resulted in an approximately 170% increase in hemagglutination titer compared to wild-type H3 hemagglutinin.
[0172] Thus, the residue at position 431 of the H3 hemagglutinin can be modified to a non-leucine residue. For example, the residue at position 431 can be modified to a methionine residue or a conservative methionine substitution, such as leucine, isoleucine, glutamine, valine, or phenylalanine.
[0173] For example, the modified H3 hemagglutinin protein may have an amino acid sequence having about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the amino acid sequence of the hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 92), wherein the amino acid sequence has a methionine or a conservative methionine substitution at position 431, wherein the sequence is not naturally present, and wherein the hemagglutinin protein forms VLPs when expressed. The conservative methionine substitution may be, for example, leucine, isoleucine, glutamine, valine or phenylalanine.
[0174] The present specification also provides a nucleic acid comprising a nucleotide sequence encoding a modified H3 hemagglutinin having a substitution at position 431 as described above and operably linked to a regulatory domain active in plants.
[0175] For example, the nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity therebetween with a nucleotide sequence encoding a hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 102), wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having a methionine or conservative methionine substitution at position 431, wherein the sequence is not naturally present, and wherein the nucleotide sequence encodes a hemagglutinin protein that forms VLPs when expressed. The conservative methionine substitution may be, for example, leucine, isoleucine, glutamine, valine or phenylalanine.
[0176] The nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity thereto with the nucleotide sequence of SEQ ID NO: 102, wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having a methionine or conservative methionine substitution at position 431, wherein the sequence is not naturally present, and wherein the nucleotide sequence encodes a hemagglutinin protein that forms VLPs when expressed. The conservative aspartic acid substitution may be, for example, leucine, isoleucine, glutamine, valine or phenylalanine.
[0177] In addition, a method of producing VLPs in plants is provided, the VLPs comprising a modified H3 hemagglutinin as described above having a substitution at position 431. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0178] In addition, a method for increasing the yield of VLPs in a plant is provided, the VLPs comprising a modified H3 hemagglutinin as described above having a substitution at least at position 431. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0179] The present specification also provides a VLP comprising a H3 hemagglutinin having a substitution at least at position 431. The VLP can be produced by the method provided in the present specification. Compared with a VLP comprising an unmodified H3 hemagglutinin protein, the VLP protein comprising the modified H3 hemagglutinin exhibits improved properties.
[0180] B. H3 hemagglutinin substitution II
[0181] Modification of positions 382, 384, 392, 431 and / or 524-528 ("CysTM")
[0182] A modified H3 influenza virus hemagglutinin protein and a method of producing the modified H3 influenza virus hemagglutinin protein in plants are described herein. It has been observed that modification of specific amino acids in a hemagglutinin protein from an H3 subtype results in improved properties of the modified H3 hemagglutinin protein compared to a wild-type H3 hemagglutinin protein or an unmodified H3 hemagglutinin protein.
[0183] In one aspect, the cysteine residues at positions 524 and / or 528 (H3 A / Hong Kong / 4801 / 14 numbering, SEQ ID NO: 92) or residues equivalent to these positions determined by comparison may be substituted with non-cysteine residues at these positions. In addition, the residues at positions 525, 526 and / or 527 (H3 A / Hong Kong / 4801 / 14 hemagglutinin numbering) may also be modified. These modifications or substitutions may be referred to as "CysTM modification", "CysTM", "CysTM mutation", "CysTM substitution" or "CysTM replacement", or grammatically equivalent expressions.
[0184] Holtz et al. U.S. application 13 / 838,796 and its companion document (BMC Biotechnology. 2014; 14: 111) teach to improve the stability of recombinant hemagglutinin and maintain its potency by mutation of cysteine residues in the carboxyl terminal domain of the hemagglutinin protein (including the transmembrane domain (TM) and the cytoplasmic domain (CT)). Specifically, Holtz et al. demonstrated C539A, C546A, C549A, C524S and C528A mutations in recombinant Perth / 16 / 2009 hemagglutinin (H3N2). Mutations of all five cysteine residues or their different subsets resulted in hemagglutinin yields, purity, particle size, hemagglutination activity and thermal stability comparable to recombinant wild-type hemagglutinin protein. In contrast, mutations of a pair of conserved cysteine residues in the extracellular domain known to form disulfide bonds (C64S and C76S) resulted in a significant reduction in hemagglutinin expression, indicating the key role of these residues in the correct folding of hemagglutinin. By using a single radial immunodiffusion assay (SRID), Holtz et al. also showed that mutation of these five cysteine residues increased the potency of recombinant hemagglutinin by preventing disulfide cross-linking in the TM and CT domains compared to the wild-type protein. The mutant hemagglutinin protein maintained potency for at least 12 months at 25°C, whereas the wild-type hemagglutinin protein showed less than 40% potency after only 50 days after purification.
[0185] Xu et al. (Virus Genes (2013) 47: 20-26) showed that mutant H3 hemagglutinin with one or two TM cysteine (C540 / 544) mutations can be normally expressed in cells, but compared with the wild-type H3 hemagglutinin protein, the mutant exhibited lower heat resistance and enhanced fusion activity.
[0186] In order to improve the properties of the H3 hemagglutinin protein, a total of 33 single modifications, double modifications or triple modifications were tested in combination with the transmembrane modification described herein ("CysTM modification"). As described herein and shown in the examples, only modifications at specific positions or combinations of modifications improved the properties of the H3 hemagglutinin protein. Modifications at 13 positions or combinations of these positions had adverse effects on the properties of the H3 hemagglutinin protein (data not shown).
[0187] Examples of improved properties of H3 hemagglutinin mutant proteins include: increased production of hemagglutinin protein when expressed in plant cells, compared to wild-type or unmodified hemagglutinin of the same influenza strain or subtype that does not comprise the modification or mutation; increased hemagglutination titer of the modified or mutated hemagglutinin protein compared to the wild-type or unmodified hemagglutinin protein; improved integrity, stability, or integrity and stability of VLPs comprising the modified hemagglutinin protein compared to the integrity or stability, or integrity and stability, of VLPs comprising the modified hemagglutinin protein; increased production of VLPs when expressed in plant cells, compared to the production of wild-type VLPs that do not comprise the modification or mutation; and combinations of these advantages.
[0188] In one aspect, a modified H3 hemagglutinin is provided, wherein the cysteine residues at positions 524 and / or 528 of the modified H3 hemagglutinin (H3 A / Hong Kong / 4801 / 14 numbering) or residues equivalent to these positions determined by alignment are substituted with non-cysteine residues at these positions. For example, the cysteine residue at position 524 may be substituted with serine or a conservative serine substitution, or the cysteine at position 528 may be substituted with leucine or a conservative leucine substitution.
[0189] In addition, the sequence between the two cysteines at positions 524 and 528 (A / Hong Kong / 4801 / 14 numbering, SEQ ID NO: 92) can also be modified. 524 X 525 X 526 X 527 C 528 ", C 524 (Position 524) can be substituted with serine (S, Ser) or a conservative serine substitution; if X 525 (position 525) is not leucine, then residue X 525 Can be substituted with leucine (L, Leu) or conservative leucine substitution; if X 526 (Position 526) is not valine, then X 526 Can be substituted with valine (V, Val) or conservative valine substitution; if X 527(Position 527) is not leucine, then position X 527 The residue at position 1 can be substituted with leucine (L, Leu) or a conservative leucine substitution, C 528 (Position 528) can be substituted with leucine (L, Leu) or a conservative leucine substitution. For example, in one embodiment, the sequence "CFLLC" at positions 524 to 528 can be replaced with the sequence "SLVLL" (SEQ ID NO: 98).
[0190] In addition to H3 influenza viruses having cysteine residues at positions 524 and / or 528, or residues equivalent to these positions as determined by alignment, hemagglutinin proteins from other strains can also be modified as described herein. For example, a hemagglutinin protein from an influenza B virus strain having cysteine residues at positions equivalent to positions 524 and / or 528 of an H3 hemagglutinin can be modified to have a non-cysteine residue as described herein.
[0191] In addition to mutations in the transmembrane domain as described herein, the modified H3 hemagglutinin protein may also include one or more amino acid substitutions at positions 382, 384, 392 and / or 431, which results in improved properties of the modified HA3 protein or VLPs produced using the modified hemagglutinin protein. It should be understood that the improved properties are not limited to replacing specific amino acids at specific sites, as those skilled in the art will understand that amino acids with similar properties can replace the amino acids at the determined positions.
[0192] Therefore, the modified H3 hemagglutinin protein or mutated H3 hemagglutinin protein described herein is different from the reference strain H3 A / Hong Kong / 4801 / 14 hemagglutinin (SEQ ID NO: 92; see Figure 1 ) comprises one or more mutations or modifications at any one or more residues in the sequence alignment of positions 382, 384, 392, 431, 524, 525, 526, 527 or 528. Thus, an H3 influenza virus hemagglutinin polypeptide, protein and / or protein complex, such as a virus-like particle (VLP), is provided, the VLP comprising a modification or mutation at one or more of amino acid positions 382, 384, 392, 431, 524, 525, 526, 527 or 528 (such amino acid numbering is based on the sequence alignment of positions 382, 384, 392, 431, 524, 525, 526, 527 or 528). Figure 1 The sequence of H3 A / Hong Kong / 4801 / 14 shown in the figure (SEQ ID NO: 92)), or includes a modification or mutation at an amino acid position corresponding to such an amino acid position, which is determined, for example, by alignment of the hemagglutinin amino acid sequence with SEQ ID NO: 92. Non-limiting examples of H3 influenza virus hemagglutinin amino acid sequences that include one or more such mutations include SEQ ID NOs: 91, 92, 93, 94, 95, 96, and 97.
[0193] The modified H3 hemagglutinin proteins described herein include H3 hemagglutinin proteins having an amino acid sequence that has about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% sequence identity or sequence similarity, or any amount in between, to the amino acid sequence encoding the hemagglutinin from H3 (SEQ ID NOs: 91-97), wherein the amino acid sequence has one or more mutations or modifications at any one or more residues corresponding to the sequence at position 382, 384, 392, 431, 524, 525, 526, 527 or 528 of the H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 92) hemagglutinin.
[0194] In addition, the H3 hemagglutinin protein may be encoded by a nucleotide sequence having a sequence identity or sequence similarity of about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100%, or any amount in between these values, to a nucleotide sequence encoding a hemagglutinin from H3 (SEQ ID NOs: 91-97 of an H3 strain), wherein the H3 hemagglutinin protein has one or more mutations or modifications at any one or more residues positioned opposite to positions 382, 384, 392, 431, 524, 525, 526, 527, or 528 of the H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 92) hemagglutinin, and wherein the nucleotide sequence encodes a hemagglutinin protein that forms VLPs when expressed.
[0195] Non-limiting examples of strains from which H3 hemagglutinins can be derived include A / Bangkok / 3007 / 15(H3N2) (SEQ ID NO: 91); A / Hongkong / 4801 / 14(H3N2) (SEQ ID NO: 92); A / Minnesota / 40 / 15(H3N2) (SEQ ID NO: 93); A / South Australia / 1 / 16(H3N2) (SEQ ID NO: 94); A / Pennsylvania / 09 / 15(H3N2) (SEQ ID NO: 95); A / Switzerland / 9715293 / 13(H3N2) (SEQ ID NO: 96) and A / Mississippi / 16 / 16(H3N2) (SEQ ID NO: 97).
[0196] Modification at positions 524-528 (CysTM)
[0197] In another aspect, an H3 hemagglutinin is provided, which may have a modified residue at position 382 and may not be modified to have a cysteine residue at position 524 and / or 528 (H3 A / Hongkong / 4801 / 14 numbering, SEQ ID NO: 92). In addition, the residues at positions 525, 526 and / or 527 (H3 A / Hongkong / 4801 / 14 numbering) may also be modified.
[0198] For example, Fig. 7A , 7B As shown in FIGS. 7C , H3 hemagglutinin in which the cysteine residues at positions 524 and 528 were modified to non-cysteine and the residue at position 382 was modified from asparagine to alanine resulted in an approximately 260% increase in hemagglutination titer compared to the wild-type H3 hemagglutinin.
[0199] Thus, a modified H3 hemagglutinin protein is provided, comprising one or more modifications at positions 524, 525, 526, 527 or 528 and a modification at position 382. In a non-limiting example, the modified H3 hemagglutinin has modifications at least at positions 382, 524 and 528.
[0200] The residue at position 382 of H3 hemagglutinin can be modified to a non-asparagine. For example, the residue at position 382 can be modified to a hydrophobic amino acid, such as alanine or a conservative alanine substitution, such as serine (S, Ser), glycine (G, Gly), threonine (T, Thr), cysteine (C, Cys) or valine (V, Val). The residue at position 524 can be modified to a non-cysteine, such as serine (S, Ser) or a conservative serine substitution, and the residue at position 528 can be modified to a non-cysteine, such as leucine (L, Leu) or a conservative leucine substitution.
[0201] For example, the modified H3 hemagglutinin protein may have an amino acid sequence having about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the amino acid sequence of the hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 92), wherein the amino acid sequence has an alanine (A, Ala) or conservative alanine (A, Ala) substitution at position 382, and there are no cysteine residues at positions 524 and 528, wherein the sequence is not naturally present, and wherein the hemagglutinin forms VLPs when expressed. The conservative alanine substitution may be, for example, serine (S, Ser), glycine (G, Gly), threonine (T, Thr), cysteine (C, Cys) or valine (V, Val). The non-cysteine at position 524 can be serine (S, Ser) or a conservative serine substitution, and the non-cysteine at position 528 can be leucine (L, Leu) or a conservative leucine substitution. The conservative serine substitution can be, for example, threonine, alanine, asparagine, aspartic acid, glutamine, glycine, glutamic acid or lysine. The conservative leucine substitution can be, for example, isoleucine (I, Ile), valine (V, Val), methionine (M, Met), phenylalanine (F, Phe) or valine (V, Val).
[0202] The present invention also provides a nucleic acid comprising a nucleotide sequence encoding a modified H3 hemagglutinin having substitutions at positions 382, 524 and 528 as described above and operably linked to a regulatory domain active in plants.
[0203] For example, the nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the nucleotide sequence encoding the hemagglutinin from H3 A / Hongkong / 4801 / 14 (SEQ ID NO: 102), wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having an alanine (A, Ala) or conservative alanine (A, Ala) substitution at position 382, and no cysteine residues at positions 524 and 528, wherein the sequence is not naturally present, and wherein the hemagglutinin forms VLPs when expressed. The conservative alanine substitution may be, for example, serine (S, Ser), glycine (G, Gly), threonine (T, Thr), cysteine (C, Cys) or valine (V, Val). The non-cysteine at position 524 can be serine (S, Ser) or a conservative serine substitution, and the non-cysteine at position 528 can be leucine (L, Leu) or a conservative leucine substitution. The conservative serine substitution can be, for example, threonine, alanine, asparagine, aspartic acid, glutamine, glycine, glutamic acid or lysine. The conservative leucine substitution can be, for example, isoleucine (I, Ile), valine (V, Val), methionine (M, Met), phenylalanine (F, Phe) or valine (V, Val).
[0204] The nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the nucleotide sequence of SEQ ID NO: 102, wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having an alanine (A, Ala) or conservative alanine (A, Ala) substitution at position 382, and no cysteine residues at positions 524 and 528, wherein the sequence is not naturally present, and wherein the hemagglutinin forms VLPs when expressed. The conservative alanine substitution may be, for example, serine (S, Ser), glycine (G, Gly), threonine (T, Thr), cysteine (C, Cys) or valine (V, Val).
[0205] The modified H3 hemagglutinin may have other modified residues in addition to the residues at positions 382, 524, and 528. For example, the residues at one or more of positions 384, 525, 526, and 527 may be modified. In a non-limiting example, the modified H3 hemagglutinin may have substituted residues at positions 382, 524, 528, and one or more substituents at positions 384, 525, 526, 527, or a combination thereof.
[0206] In addition, a method for producing VLPs in plants is provided, the VLPs comprising a modified H3 hemagglutinin having substitutions at least at positions 382, 524, 528 as described above and optionally at positions 384, 525, 526, 527. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0207] In addition, a method for increasing the yield of VLPs in a plant is provided, the VLPs comprising a modified H3 hemagglutinin having substitutions at least at positions 382, 524 and 528 as described above and optionally at positions 384, 525, 526 and 527. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0208] The present specification also provides a VLP, which includes an H3 hemagglutinin having substitutions at least at positions 382, 524 and 528 and optionally at positions 384, 525, 526 and 527. The VLP can be produced by the method provided by the present specification. Compared with a VLP including an unmodified H3 hemagglutinin protein, the VLP protein including the modified H3 hemagglutinin shows improved properties.
[0209] Modifications at positions 524-528 (CysTM) and 384
[0210] In another aspect, an H3 hemagglutinin is provided, which may have a modified residue at position 384 and may be modified to have no cysteine residue at positions 524 and 528 (H3 A / Hongkong / 4801 / 14 numbering, SEQ ID NO: 92). In addition, the residues at positions 525, 526 and / or 527 (H3 A / Hongkong / 4801 / 14 numbering) may also be modified.
[0211] For example, Fig. 7A , 7B As shown in FIGS. 7C , H3 hemagglutinin in which the cysteine residues at positions 524 and 528 were modified to non-cysteine residues and the residue at position 384 was modified from leucine to valine resulted in an approximately 270% increase in hemagglutination titer compared to the wild-type H3 hemagglutinin.
[0212] Thus, a modified H3 hemagglutinin protein is provided, comprising one or more modifications at positions 524, 525, 526, 527 or 528 and a modification at position 384. In a non-limiting example, the modified H3 hemagglutinin has modifications at least at positions 384, 524 and 528.
[0213] The residue at position 384 of H3 hemagglutinin can be modified to a non-leucine residue. For example, the residue at position 384 can be modified to another hydrophobic amino acid, such as valine or a conservative valine substitution, such as isoleucine, leucine, methionine, alanine or threonine.
[0214] For example, the modified H3 hemagglutinin protein may have an amino acid sequence having about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the amino acid sequence of the hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 92), wherein the amino acid sequence has a valine or a conservative valine substitution at position 384, and there are no cysteine residues at positions 524 and 528, wherein the sequence is not naturally occurring, and wherein the hemagglutinin forms VLPs when expressed. The conservative valine substitution may be, for example, isoleucine, leucine, methionine, alanine or threonine.
[0215] The present invention also provides a nucleic acid comprising a nucleotide sequence encoding a modified H3 hemagglutinin having substitutions at positions 384, 524 and 528 as described above and operably linked to a regulatory domain active in plants.
[0216] For example, the nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the nucleotide sequence encoding the hemagglutinin from H3 A / Hongkong / 4801 / 14 (SEQ ID NO: 102), wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having a valine or conservative valine substitution at position 384 and no cysteine residues at positions 524 and 528, and wherein the sequence is not naturally occurring. The conservative substitution may be, for example, isoleucine, leucine, methionine, alanine or threonine.
[0217] The nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity thereto with the nucleotide sequence of SEQ ID NO: 102, wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having a valine or conservative valine substitution at position 384 and no cysteine residues at positions 524 and 528, wherein the sequence is not naturally occurring, and wherein the hemagglutinin forms VLPs when expressed. The conservative valine substitution may be, for example, isoleucine, leucine, methionine, alanine or threonine.
[0218] The modified H3 hemagglutinin may have other modified residues in addition to the residues at positions 384, 524, and 528. For example, the residues at one or more of positions 382, 525, 526, and 527 may be modified. In a non-limiting example, the modified H3 hemagglutinin may have substituted residues at positions 384, 524, 528, and one or more substituents at positions 382, 525, 526, 527, or a combination thereof.
[0219] In addition, a method for producing VLPs in plants is provided, the VLPs comprising a modified H3 hemagglutinin having substitutions at least at positions 384, 524, 528 as described above and optionally at positions 382, 525, 526, 527. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0220] In addition, a method of increasing the yield of VLPs in a plant is provided, the VLPs comprising a modified H3 hemagglutinin having substitutions at least at positions 384, 524 and 528 as described above and optionally at positions 382, 525, 526 and 527. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0221] The present specification also provides a VLP, which includes an H3 hemagglutinin having substitutions at least at positions 384, 524 and 528 and optionally at positions 382, 525, 526 and 527. The VLP can be produced by the method provided by the present specification. Compared with a VLP including an unmodified H3 hemagglutinin protein, the VLP protein including the modified H3 hemagglutinin shows improved properties.
[0222] Modifications at positions 524-528 (CysTM) and 392
[0223] In another aspect, an H3 hemagglutinin is provided, which may have a modified residue at position 392 and may not have a cysteine residue at positions 524 and 528 (H3 A / Hongkong / 4801 / 14 numbering, SEQ ID NO: 92). In addition, the residues at positions 525, 526 and / or 527 (H3 A / Hongkong / 4801 / 14 numbering) may also be modified.
[0224] For example, Fig. 7A and 7B As shown, H3 hemagglutinin in which the cysteine residues at positions 524 and 528 were modified to non-cysteine and the residue at position 392 was modified from phenylalanine to aspartic acid resulted in an approximately 200% to 270% increase in hemagglutination titer compared to the wild-type H3 hemagglutinin.
[0225] Thus, a modified H3 hemagglutinin protein is provided, comprising one or more modifications at positions 524, 525, 526, 527 or 528 and a modification at position 392. In a non-limiting example, the modified H3 hemagglutinin has modifications at least at positions 392, 524 and 528.
[0226] The residue at position 392 of H3 hemagglutinin can be modified to a non-phenylalanine. For example, the residue at position 392 can be modified to a charged amino acid, such as aspartic acid or a conservative aspartic acid replacement, such as glutamine, asparagine, glutamic acid or serine.
[0227] For example, the modified H3 hemagglutinin protein may have an amino acid sequence with about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the amino acid sequence of the hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 92), wherein the amino acid sequence has aspartic acid or a conservative aspartic acid substitution at position 392, and there is no cysteine residue at positions 524 and 528, wherein the sequence is not naturally present, and wherein the hemagglutinin forms VLPs when expressed. The conservative aspartic acid substitution may be, for example, glutamine, asparagine, glutamic acid or serine. The non-cysteine at position 524 may be serine (S, Ser) or a conservative serine substitution, and the non-cysteine at position 528 may be leucine (L, Leu) or a conservative leucine substitution. The conservative serine substitution can be, for example, threonine, alanine, asparagine, aspartic acid, glutamine, glycine, glutamic acid or lysine. The conservative leucine substitution can be, for example, isoleucine (I, Ile), valine (V, Val), methionine (M, Met), phenylalanine (F, Phe) or valine (V, Val).
[0228] The present invention also provides a nucleic acid comprising a nucleotide sequence encoding a modified H3 hemagglutinin having substitutions at positions 392, 524 and 528 as described above and operably linked to a regulatory domain active in plants.
[0229] For example, the nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity thereto with a nucleotide sequence encoding a hemagglutinin from H3 A / Hongkong / 4801 / 14 (SEQ ID NO: 102), wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having an aspartic acid or conservative aspartic acid substitution at position 392 and no cysteine residues at positions 524 and 528, wherein the sequence is not naturally present, and wherein the hemagglutinin forms VLPs when expressed. The conservative substitution may be, for example, glutamine, asparagine, glutamic acid or serine.
[0230] The nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity thereto with the nucleotide sequence of SEQ ID NO: 102, wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having an aspartic acid or conservative aspartic acid substitution at position 392 and no cysteine residues at positions 524 and 528, wherein the sequence is not naturally present, and wherein the hemagglutinin forms VLPs when expressed. The conservative substitution may be, for example, glutamine, asparagine, glutamic acid or serine.
[0231] The modified H3 hemagglutinin may have other modified residues in addition to the residues at positions 392, 524, and 528. For example, the residues at one or more of positions 525, 526, and 527 may be modified. In a non-limiting example, the modified H3 hemagglutinin may have substituted residues at positions 392, 524, 528, and one or more substituents at positions 525, 526, 527, or a combination thereof.
[0232] In addition, a method for producing VLPs in plants is provided, the VLPs comprising a modified H3 hemagglutinin having substitutions at least at positions 392, 524, 528 as described above and optionally at positions 525, 526, 527. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0233] In addition, a method of increasing the yield of VLPs in a plant is provided, the VLPs comprising a modified H3 hemagglutinin having substitutions at least at positions 392, 524 and 528 as described above and optionally at positions 525, 526 and 527. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0234] The present specification also provides a VLP, which includes an H3 hemagglutinin having substitutions at least at positions 392, 524 and 528 and optionally at positions 525, 526 and 527. The VLP can be produced by the method provided by the present specification. Compared with a VLP including an unmodified H3 hemagglutinin protein, the VLP protein including the modified H3 hemagglutinin shows improved properties.
[0235] Modifications at positions 524-528 (CysTM) and 431
[0236] In another aspect, an H3 hemagglutinin is provided, which may have a modified residue at position 431 and may not have a cysteine residue at positions 524 and 528 (H3 A / Hongkong / 4801 / 14 numbering, SEQ ID NO: 92). In addition, the residues at positions 525, 526 and / or 527 (H3 A / Hongkong / 4801 / 14 numbering) may also be modified.
[0237] For example, Fig. 7A and 7B As shown, H3 hemagglutinin in which the cysteine residues at positions 524 and 528 were modified to non-cysteine and the residue at position 431 was modified from leucine to methionine resulted in an approximately 250% increase in hemagglutination titer compared to the wild-type H3 hemagglutinin.
[0238] Thus, a modified H3 hemagglutinin protein is provided, comprising one or more modifications at positions 524, 525, 526, 527 or 528 and a modification at position 431. In a non-limiting example, the modified H3 hemagglutinin has modifications at least at positions 431, 524 and 528.
[0239] The residue at position 431 of H3 hemagglutinin can be modified to a non-leucine residue. For example, the residue at position 431 can be modified to a methionine residue or a conservative methionine substitution, such as leucine, isoleucine, glutamine, valine, or phenylalanine.
[0240] For example, the modified H3 hemagglutinin protein may have an amino acid sequence with about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity thereto with the amino acid sequence of the hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 92), wherein the amino acid sequence has a methionine or conservative methionine substitution at position 431, and there is no cysteine residue at positions 524 and 528, wherein the sequence is not naturally present, and wherein the hemagglutinin forms VLPs when expressed. The conservative methionine substitution may be, for example, leucine, isoleucine, glutamine, valine or phenylalanine. The non-cysteine at position 524 may be serine (S, Ser) or a conservative serine substitution, and the non-cysteine at position 528 may be leucine (L, Leu) or a conservative leucine substitution. The conservative serine substitution can be, for example, threonine, alanine, asparagine, aspartic acid, glutamine, glycine, glutamic acid or lysine. The conservative leucine substitution can be, for example, isoleucine (I, Ile), valine (V, Val), methionine (M, Met), phenylalanine (F, Phe) or valine (V, Val).
[0241] The present invention also provides a nucleic acid comprising a nucleotide sequence encoding a modified H3 hemagglutinin having substitutions at positions 431, 524 and 528 as described above and operably linked to a regulatory domain active in plants.
[0242] For example, the nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the nucleotide sequence encoding the hemagglutinin from H3 A / Hongkong / 4801 / 14 (SEQ ID NO: 102), wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having a methionine or conservative methionine substitution at position 431 and no cysteine residues at positions 524 and 528, wherein the sequence is not naturally occurring, and wherein the hemagglutinin forms VLPs when expressed. The conservative substitution may be, for example, leucine, isoleucine, glutamine, valine or phenylalanine.
[0243] The nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity thereto with the nucleotide sequence of SEQ ID NO: 102, wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having a methionine or conservative methionine substitution at position 431 and having no cysteine residues at positions 524 and 528, wherein the sequence is not naturally present, and wherein the hemagglutinin forms VLPs when expressed. The conservative substitution may be, for example, leucine, isoleucine, glutamine, valine or phenylalanine.
[0244] The modified H3 hemagglutinin may have other modified residues in addition to the residues at positions 431, 524, and 528. For example, the residues at one or more of positions 525, 526, and 527 may be modified. In a non-limiting example, the modified H3 hemagglutinin may have substituted residues at positions 431, 524, 528, and one or more substituents at positions 525, 526, 527, or a combination thereof.
[0245] In addition, a method for producing VLPs in plants is provided, the VLPs comprising a modified H3 hemagglutinin having substitutions at least at positions 431, 524, 528 as described above and optionally at positions 525, 526, 527. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0246] In addition, a method of increasing the yield of VLPs in a plant is provided, the VLPs comprising a modified H3 hemagglutinin having substitutions at least at positions 431, 524 and 528 as described above and optionally at positions 525, 526 and 527. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0247] The present specification also provides a VLP, which includes an H3 hemagglutinin having substitutions at least at positions 431, 524 and 528 and optionally at positions 525, 526 and 527. The VLP can be produced by the method provided by the present specification. Compared with a VLP including an unmodified H3 hemagglutinin protein, the VLP protein including the modified H3 hemagglutinin shows improved properties.
[0248] Modifications at positions 524-528 (CysTM), 382 and 384
[0249] In another aspect, an H3 hemagglutinin is provided, which may have modified residues at positions 382 and 384, and may not have cysteine residues at positions 524 and 528 (H3 A / Hongkong / 4801 / 14 numbering, SEQ ID NO: 92). In addition, residues at positions 525, 526 and / or 527 (H3 A / Hongkong / 4801 / 14 numbering) may also be modified.
[0250] For example, Fig. 7E As shown, H3 hemagglutinin in which the cysteine residues at positions 524 and 528 were modified to non-cysteine, the residue at position 382 was modified from asparagine to alanine, and the residue at position 384 was modified from leucine to valine resulted in an approximately 400% to 500% increase in hemagglutination titer compared to the wild-type H3 hemagglutinin.
[0251] Thus, a modified H3 hemagglutinin protein is provided, comprising one or more modifications at positions 524, 525, 526, 527 or 528, and modifications at positions 382 and 384. In a non-limiting example, the modified H3 hemagglutinin has modifications at least at positions 382, 384, 524 and 528.
[0252] The residue at position 382 of the H3 hemagglutinin can be modified to a non-asparagine. For example, the residue at position 382 can be modified to a hydrophobic amino acid, such as alanine or a conservative alanine substitution, such as serine (S, Ser), glycine (G, Gly), threonine (T, Thr), cysteine (C, Cys) or valine (V, Val). The residue at position 384 of the H3 hemagglutinin can be modified to a non-leucine. For example, the residue at position 384 can be modified to another hydrophobic amino acid, such as valine or a conservative valine substitution, such as isoleucine, leucine, methionine, alanine or threonine.
[0253] For example, the modified H3 hemagglutinin protein may have an amino acid sequence having about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the amino acid sequence of the hemagglutinin from H3 A / Hong Kong / 4801 / 14 (SEQ ID NO: 92), wherein the amino acid sequence has an alanine (A, Ala) or conservative alanine (A, Ala) substitution at position 382, a valine or conservative valine substitution at position 384, and no cysteine residues at positions 524 and 528, and wherein the sequence is not naturally occurring, and wherein the hemagglutinin forms VLPs when expressed. The conservative alanine substitution may be, for example, serine (S, Ser), glycine (G, Gly), threonine (T, Thr), cysteine (C, Cys) or valine (V, Val). The conservative valine substitution can be, for example, isoleucine (I, Ile), leucine (L, Leu), methionine (M, Met), alanine (A, Ala) or threonine (T, Thr). The non-cysteine at position 524 can be serine (S, Ser) or a conservative serine substitution, and the non-cysteine at position 528 can be leucine (L, Leu) or a conservative leucine substitution. The conservative serine substitution can be, for example, threonine, alanine, asparagine, aspartic acid, glutamine, glycine, glutamic acid or lysine. The conservative leucine substitution can be, for example, isoleucine (I, Ile), valine (V, Val), methionine (M, Met), phenylalanine (F, Phe) or valine (V, Val).
[0254] The present invention also provides a nucleic acid comprising a nucleotide sequence encoding a modified H3 hemagglutinin having substitutions at positions 382, 384, 524 and 528 as described above and operably linked to a regulatory domain active in plants.
[0255] For example, the nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the nucleotide sequence encoding the hemagglutinin from H3 A / Hongkong / 4801 / 14 (SEQ ID NO: 102), wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having an alanine (A, Ala) or a conservative alanine (A, Ala) substitution at position 382, a valine or a conservative valine substitution at position 384, and no cysteine residues at positions 524 and 528, and wherein the sequence is not naturally occurring, and wherein the hemagglutinin forms VLPs when expressed. The conservative alanine substitution may be, for example, serine (S, Ser), glycine (G, Gly), threonine (T, Thr), cysteine (C, Cys) or valine (V, Val). The conservative valine substitution may be, for example, isoleucine (I, Ile), leucine (L, Leu), methionine (M, Met), alanine (A, Ala) or threonine (T, Thr). The non-cysteine at position 524 may be serine (S, Ser) or a conservative serine substitution, and the non-cysteine at position 528 may be leucine (L, Leu) or a conservative leucine substitution. The conservative serine substitution may be, for example, threonine, alanine, asparagine, aspartic acid, glutamine, glycine, glutamic acid or lysine. The conservative leucine substitution may be, for example, isoleucine (I, Ile), valine (V, Val), methionine (M, Met), phenylalanine (F, Phe) or valine (V, Val).
[0256] The nucleotide sequence may have about 70, 75, 80, 85, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or any amount of sequence identity or sequence similarity with the nucleotide sequence of SEQ ID NO: 102, wherein the nucleotide sequence encodes a modified H3 hemagglutinin protein having alanine (A, Ala) or conservative alanine (A, Ala) substitution at position 382, valine or conservative valine substitution at position 384, and no cysteine residues at positions 524 and 528, and wherein the sequence is not naturally occurring, and wherein the hemagglutinin forms VLPs when expressed. The conservative alanine substitution may be, for example, serine (S, Ser), glycine (G, Gly), threonine (T, Thr), cysteine (C, Cys) or valine (V, Val). The conservative valine substitution can be, for example, isoleucine (I, Ile), leucine (L, Leu), methionine (M, Met), alanine (A, Ala) or threonine (T, Thr). The non-cysteine at position 524 can be serine (S, Ser) or a conservative serine substitution, and the non-cysteine at position 528 can be leucine (L, Leu) or a conservative leucine substitution. The conservative serine substitution can be, for example, threonine, alanine, asparagine, aspartic acid, glutamine, glycine, glutamic acid or lysine. The conservative leucine substitution can be, for example, isoleucine (I, Ile), valine (V, Val), methionine (M, Met), phenylalanine (F, Phe) or valine (V, Val).
[0257] The modified H3 hemagglutinin may have other modified residues in addition to the residues at positions 382, 384, 524, and 528. For example, the residues at one or more of positions 525, 526, and 527 may be modified. In a non-limiting example, the modified H3 hemagglutinin may have substituted residues at positions 382, 384, 524, 528, and one or more substituents at positions 525, 526, 527, or a combination thereof.
[0258] In addition, a method for producing VLPs in plants is provided, the VLPs comprising a modified H3 hemagglutinin having substitutions at least at positions 382, 384, 524, 528 as described above and optionally at positions 525, 526, 527. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0259] In addition, a method of increasing the yield of VLPs in a plant is provided, the VLPs comprising a modified H3 hemagglutinin having substitutions at least at positions 382, 384, 524 and 528 as described above and optionally at positions 525, 526 and 527. The method comprises introducing into a plant or plant part a nucleic acid encoding a modified H3 hemagglutinin operably linked to a regulatory domain active in a plant, and incubating the plant or plant part under conditions allowing expression of the nucleic acid, thereby producing VLPs.
[0260] The present specification also provides a VLP, which includes an H3 hemagglutinin having substitutions at least at positions 382, 384, 524 and 528 and optionally at positions 525, 526 and 527. The VLP can be produced by the method provided by the present specification. Compared with a VLP including an unmodified H3 hemagglutinin protein, the VLP protein including the modified H3 hemagglutinin shows improved properties.
[0261] This article also provides a method for increasing the yield or harvest of VLPs including mutant influenza virus hemagglutinin in plants. For example, the method may include introducing a nucleic acid encoding mutant influenza virus hemagglutinin as described herein into a plant, a plant part or a plant cell. The nucleic acid encoding mutant influenza virus hemagglutinin can be optimized for the use of human codons, the GC content of improvement or a combination thereof. One or more mutant influenza virus hemagglutinin proteins can be expressed in plants, plant parts or plant cells to produce VLPs including one or more mutant influenza virus hemagglutinin proteins. Alternatively, the method may include providing a plant, a plant part or a plant cell comprising a nucleic acid encoding mutant influenza virus hemagglutinin protein to produce VLPs including one or more mutant influenza virus hemagglutinin proteins.
[0262] The method for producing VLPs comprising mutant influenza virus hemagglutinin may also include the step of introducing a second nucleic acid sequence into a plant, a plant part or a plant cell, wherein the second nucleic acid encodes a proton channel protein co-expressed with the mutant influenza virus hemagglutinin. For example, the proton channel protein may be an influenza A virus M2 subtype protein, such as A / New Caledonia / 20 / 99 M2. The co-expression of the proton channel protein may result in an increase in the accumulation of mutant influenza virus hemagglutinin protein and / or VLPs comprising the mutant influenza virus hemagglutinin protein, such as described in WO 2013 / 044390, which is incorporated herein by reference.
[0263] In addition, the mutant influenza virus hemagglutinin may further comprise a modified proteolytic loop or cleavage site as described in WO 2013 / 044390 and WO 2014 / 153674, which are incorporated herein by reference.
[0264] "Coexpression" refers to the introduction and expression of two or more nucleotide sequences in plants, plants or plant cells, each of which encodes a fragment of a protein of interest or a protein of interest. The two or more nucleotide sequences can be introduced into plants, plant parts or plant cells in a carrier so that each of the two or more nucleotide sequences is under the control of an independent regulatory domain (e.g., comprising a double construct). Alternatively, the two or more nucleotide sequences can be introduced in an independent carrier (e.g., comprising a single construct), and each carrier includes an appropriate regulatory domain for the expression of the corresponding nucleic acid. For example, two nucleotide sequences that are respectively located on an independent carrier and introduced into an independent Agrobacterium tumefaciens host can be mixed to achieve coexpression by mixing the required amount of each Agrobacterium tumefaciens host's suspension (e.g., equal amounts, or the ratio of each Agrobacterium tumefaciens host can be changed) before vacuum infiltration. In this way, the co-infiltration of multiple Agrobacterium tumefaciens host suspensions allows the coexpression of multiple transgenics.
[0265] The nucleic acid encoding the mutant influenza virus hemagglutinin as described herein may also include a sequence that enhances the expression of the mutant influenza virus hemagglutinin in a plant, plant part or plant cell. The sequence that enhances expression may include a cowpea mosaic virus (CPMV) enhancer element operably associated with the nucleic acid encoding the mutant influenza virus hemagglutinin protein.
[0266] The nucleic acid comprising a nucleotide sequence encoding a modified influenza virus hemagglutinin (HA) as described herein may also include a sequence that enhances the expression of the hemagglutinin protein in a plant, a plant part or a plant cell. The sequence that enhances expression may include a CPMV enhancer element or a plant-derived expression enhancer operably combined with a nucleic acid encoding a modified influenza virus hemagglutinin protein. The sequence encoding the modified influenza virus hemagglutinin (HA) may also be optimized for human codon usage, increased GC content, or a combination thereof.
[0267] The term "CPMV enhancer element" as used herein refers to a nucleotide sequence encoding a 5'UTR or a modified CPMV sequence known in the art that regulates the cowpea mosaic virus (CPMV) RNA2 polypeptide. For example, CPMV enhancer elements or CPMV expression enhancers include nucleotide sequences described in WO2015 / 14367; WO2015 / 103704; WO2007 / 135480; WO2009 / 087391; Sainsbury F. and Lomonossoff GP (2008, Plant Physiol. 148: pp. 1212-1218), all of which are incorporated herein by reference. The CPMV enhancer sequence can enhance the expression of a downstream heterologous open reading frame to which it is attached. The CPMV expression enhancer may include CPMV HT, CPMVX (wherein X=160, 155, 150, 114), such as CPMV 160, CPMVX+ (wherein X=160, 155, 150, 114), such as CPMV 160+, CPMV-HT+, CPMVHT+[WT115] or CPMV HT+
[511] (WO2015 / 143567; WO2015 / 103704, which are incorporated herein by reference). The CPMV expression enhancer can be used in a plant expression system comprising a regulatory domain operably linked to a CPMV expression enhancer sequence and a nucleotide sequence of interest.
[0268] The term "CPMV enhancer element" as used herein refers to a nucleotide sequence encoding a 5'UTR or a modified CPMV sequence known in the art that regulates the cowpea mosaic virus (CPMV) RNA2 polypeptide. For example, CPMV enhancer elements or CPMV expression enhancers include nucleotide sequences described in WO2015 / 14367; WO2015 / 103704; WO2007 / 135480; WO2009 / 087391; Sainsbury F. and Lomonossoff GP (2008, Plant Physiol. 148: pp. 1212-1218), all of which are incorporated herein by reference. The CPMV enhancer sequence can enhance the expression of a downstream heterologous open reading frame to which it is attached. The CPMV expression enhancer may include CPMV HT, CPMVX, CPMVX+, CPMV-HT+, CPMVHT+[WT115] or CPMV HT+
[511] (WO2015 / 14367; WO2015 / 103704, which are incorporated herein by reference). The CPMV expression enhancer can be used in a plant expression system comprising a regulatory domain operably linked to the CPMV expression enhancer sequence and a nucleotide sequence of interest.
[0269] The term "5'UTR" or "5' untranslated region" or "5' leader sequence" refers to a domain of an mRNA that is not translated. The 5'UTR usually begins at the transcription start site and ends before the translation start site or the start codon of the coding region. The 5'UTR may regulate the stability and / or translation of the mRNA transcript.
[0270] The term "plant-derived expression enhancer" as used herein refers to a nucleotide sequence obtained from a plant that encodes a 5'UTR. An example of a plant-derived expression enhancer is described in U.S. Provisional Patent Application 2006 / 010086 (filed on March 14, 2018, which is incorporated herein by reference) or in a paper by Diamos AG et al. (2016, Front Plt Sci. 7: 1-15; which is incorporated herein by reference). The plant-derived expression enhancer can be selected from nbMT78, nbATL75, nbDJ46, nbCHP79, nbEN42, atHSP69, atGRP62, atPK65, atRP46, nb30S72, nbGT61, nbPV55, nbPPI43, nbPM64, and nbH2A86 as described in US 62 / 643,053. The plant-derived expression enhancer can be used in a plant expression system comprising a regulatory domain operably linked to the plant-derived expression enhancer sequence and a nucleotide sequence of interest.
[0271] "Operably linked" refers to specific sequences that interact directly or indirectly to perform a predetermined function, such as mediation or regulation of nucleic acid sequence expression. For example, the interaction of operably linked sequences can be mediated by a protein that interacts with the operably linked sequences.
[0272] When one or more mutant influenza virus hemagglutinin proteins are expressed in plants, plant parts or plant cells, the one or more mutant influenza virus hemagglutinin proteins self-assemble into VLPs. Plants, plant parts or plant cells can be harvested under appropriate extraction and purification conditions to maintain the integrity of VLPs, and VLPs including one or more mutant influenza virus hemagglutinins can be purified.
[0273] The present invention also provides a use of a mutant influenza virus hemagglutinin as described herein or a VLP comprising a mutant influenza virus hemagglutinin in inducing immunity to influenza infection in a subject. Also disclosed herein is an antibody or antibody fragment prepared by administering a mutant influenza virus hemagglutinin or a VLP comprising a mutant influenza virus hemagglutinin to a subject or a host animal. Also provided is a composition for inducing an immune response in a subject, the composition comprising an effective dose of a mutant influenza virus hemagglutinin as described herein or a VLP virus comprising a mutant influenza virus hemagglutinin, and a pharmaceutically acceptable carrier, adjuvant, carrier or excipient. Also provided is a vaccine for inducing an immune response in a subject, wherein the vaccine comprises an effective dose of a mutant influenza virus hemagglutinin.
[0274] Also provided herein is a method of inducing immunity to influenza infection in a subject, the method comprising administering to the subject a mutant influenza virus hemagglutinin or a VLP comprising the mutant influenza virus hemagglutinin orally, intranasally, intramuscularly, intraperitoneally, intravenously or subcutaneously.
[0275] The term "influenza virus" as used herein refers to an enveloped virus strain of the Orthomyxoviridae family characterized by having a negative-single-stranded RNA genome. Depending on the specific virus strain, the influenza virus genome consists of eight gene segments encoding 12-14 proteins.
[0276] There are four types of influenza viruses: A, B, C and D, of which influenza A or B viruses are the causative organisms of seasonal epidemics of disease in the human population. Influenza A viruses are further classified according to the expression of hemagglutinin and neuraminidase (NA) glycoprotein subtypes.
[0277] The term "hemagglutinin" or "HA" as used herein refers to a trimeric lectin that promotes the binding of influenza virus particles to sialic acid-containing proteins on the surface of target cells and mediates the release of the viral genome into target cells. There are 18 different hemagglutinin subtypes (H1-H18). The hemagglutinin protein includes two structural elements: the head, which is the main target of serum protective antibodies; and the handle. Hemagglutinin is translated into a single polypeptide HA0 (assembled as a trimer), which must be cut by a serine endoprotease between the HA1 (about 40kDa) subdomain and the HA2 (about 20kDa) subdomain. After cleavage, the two disulfide-bonded protein domains adopt the necessary conformation required to achieve viral infectivity.
[0278] The influenza A virus hemagglutinin proteins or modified influenza A virus hemagglutinin proteins disclosed herein include any known hemagglutinin proteins derived from any known influenza A strain, but also include modifications of known influenza A strains developed over time. For example, the influenza virus hemagglutinin can be derived from A / Hong Kong / 4801 / 14 (H3N2), A / Minnesota / 40 / 15 (H3N2), A / South Australia / 1 / 16 (H3N2), A / Bangkok / 3007 / 15 (H3N2), A / Switzerland / 9715293 / 13 (H3N2), A / Mississippi / 16 / 16 (H3N2), or A / Pennsylvania / 09 / 2015 (H3N2). The influenza A virus hemagglutinin may include a hemagglutinin derived from a strain, wherein the hemagglutinin has about 30-100% amino acid sequence identity, or any amount therebetween, with any hemagglutinin derived from the influenza A virus strains listed above, when the influenza virus hemagglutinin protein comprises at least one substitution as described herein and is capable of forming VLPs, inducing an immune response when administered to a subject, inducing hemagglutination, or a combination thereof.
[0279] For example, the influenza virus hemagglutinin protein can have 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100% or any amount of amino acid sequence identity therebetween to any hemagglutinin derived from the influenza A virus strains listed above, and include at least one substitution as described herein, and is capable of forming VLPs, inducing immunity, inducing hemagglutination, or a combination thereof when administered to a subject. Figure 1 The amino acid sequence alignment of multiple influenza A virus hemagglutinin domains is shown in , and these examples should not be considered limiting.
[0280] When referring to specific sequences, the terms "percent similarity", "sequence similarity", "percent identity" or "sequence identity" are used, for example, as described in the University of Wisconsin GCG software program or by manual alignment and visual inspection (see, for example, Ausubel et al., 1995 Supplement to Molecular Biology: A Laboratory Manual). Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be performed, for example, using the algorithm of Smith and Waterman (1981, Adv. Appl. Math. 2:482), by the alignment algorithm of Needleman and Wunsch (1970, J. Mol. Biol. 48:443), by the similarity search method of Pearson and Lipman (1988, Proc. Natl. Acad. Sci. USA 85:2444), or by computerized implementations of these algorithms, such as GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics software package by Genetics Computer Group, Inc., Madison, Wisconsin.
[0281] An example of an algorithm suitable for determining percent sequence identity and sequence similarity is the BLAST and BLAST 2.0 algorithms, described in Altschul et al. (1977, Nuc. Acids Res. 25: 3389-3402) and Altschul et al. (1990, J. Mol. Biol. 215: 403-410), respectively. BLAST and BLAST 2.0 are used with the parameters described herein to determine percent sequence identity for nucleic acids and proteins of the invention. For example, the BLASTN program (for nucleotide sequences) can use 11 word length (W), 10 expectation (E), M=5, N=-4, and comparison of both strands as default values. For amino acid sequences, the BLASTP program can use wordlength = 3, expectation (E) = 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff, 1989, Proc. Natl. Acad. Sci. USA 89: 10915) with alignments (B) = 50, expectation (E) = 10, M = 5, N = -4, and comparison of both chains as defaults. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (see URL: ncbi.nlm.nih.gov / ).
[0282] As used herein, the term "virus-like particle", VLP or variations thereof refers to an influenza virus particle that includes one or more influenza virus hemagglutinin proteins and self-assembles into a non-replicating, non-infectious viral capsid structure devoid of all parts of the influenza genome.
[0283] Production of influenza virus hemagglutinin protein in plants
[0284] In the case where the influenza A virus hemagglutinin protein comprises at least one substitution as described herein and is capable of forming VLPs, inducing an immune response when administered to a subject, inducing hemagglutination, or a combination thereof, the influenza A virus hemagglutinin protein comprises a polypeptide comprising a polypeptide having a sequence identical to that of influenza A virus hemagglutinin from A / Hong Kong / 4801 / 14 (H3N2, SEQ ID NO:92), A / Minnesota / 40 / 15 (H3N2 SEQ ID NO:93), A / South Australia / 1 / 16 (H3N2, SEQ ID NO:94), A / Bangkok / 3007 / 15 (H3N2, SEQ ID NO:91), A / Switzerland / 9715293 / 13 (H3N2, SEQ ID NO:96), A / Mississippi / 16 / 16 (H3N2, SEQ ID NO:97), and A / Pennsylvania / 09 / 2015 (H3N2, SEQ ID NO:95). Any hemagglutinin protein listing having an amino acid sequence of about 30 to about 100%, about 40 to about 100%, about 50 to about 100%, about 60 to about 100%, about 70 to about 100%, about 80 to about 100%, about 85 to about 100%, about 90 to about 100%, about 95 to about 100%, or about 97 to about 100%, about 98 to about 100%, or any amount therebetween.
[0285] In addition, in the case of a modified influenza virus hemagglutinin protein comprising at least one substitution as described herein and capable of forming VLPs, inducing an immune response when administered to a subject, inducing hemagglutination, or a combination thereof, the influenza virus hemagglutinin protein comprises any comprising the same sequence as SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 35, SEQ ID NO: 39, SEQ ID NO: 43, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 53, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87 8. A hemagglutinin protein having an amino acid sequence having about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 70% to about 100%, about 80% to about 100%, about 85% to about 100%, about 90% to about 100%, about 95% to about 100%, or about 97% to about 100%, about 98% to about 100%, or any amount therebetween.
[0286] As described herein, one or more specific mutations or modifications in influenza virus hemagglutinin result in increased accumulation of hemagglutinin protein and increased production of VLPs in plants compared to wild-type influenza virus hemagglutinin.
[0287] Examples of mutant influenza A virus hemagglutinin proteins having enhanced ability to produce influenza virus hemagglutinin and / or VLPs in plants include, but are not limited to:
[0288] CysTM A / Hong Kong / 4801 / 14 mutant H3 (construct number 3341, sequence number 21); N382A+L384V+CysTM A / Hong Kong / 4801 / 14 mutant H3 (construct number 3375, sequence number 25); CysTM A / Minnesota / 40 / 15 mutant H3 (construct number 3914, sequence number 27); N382A+L384V+CysTM A / Minnesota / 40 / 15 mutant H3 (construct number 3915, sequence number 30); CysTM A / S.Australia / 1 / 16 mutant H3 (construct number 3924, sequence number 33); N382A+L384V+CysTM A / S.Australia / 1 / 16 mutant H3 (Construct No. 3925, SEQ ID NO. 35); N382A+L384V+CysTM A / Bangkok / 3007 / 15 mutant H3 (Construct No. 3905, SEQ ID NO. 39); N382A A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3023, SEQ ID NO. 82); L384V A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3034, SEQ ID NO. 84); F392D A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3045, SEQ ID NO. 43); L431M A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3022, SEQ ID NO. 47); CysTM A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 2811, SEQ ID NO. 49); N382A+CysTM A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3063, SEQ ID NO. 53); L384V+CysTM A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3074, SEQ ID NO. 57); F392D+CysTM A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3085, SEQ ID NO. 59); and L431M+CysTM A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3062, SEQ ID NO. 61); CysTM A / Pennsylvania / 09 / 2015 mutant H3 (Construct No. 3313, Sequence No. 86); N382A+CysTM A / Pennsylvania / 09 / 2015 mutant H3 (Construct No. 3314, Sequence No. 88) and L384V+CysTM A / Pennsylvania / 09 / 2015 mutant H3 (Construct No. 3315, Sequence No. 90). .
[0289] Inducing immunity to influenza infection
[0290] "Immune response" generally refers to the reaction of the adaptive immune system of the subject. The adaptive immune system generally includes humoral response and cell-mediated response. Humoral response is an immune feature mediated by secretory antibodies produced in B lymphocyte lineage cells (B cells). Secreted antibodies bind to antigens on the surface of invading microorganisms (such as viruses or bacteria), which mark them for destruction. Humoral immunity is generally used to refer to antibody production and its accompanying processes, as well as the effector functions of antibodies, including Th2 cell activation and cytokine production, memory cell production, opsonin promotion of phagocytosis, pathogen elimination, etc. The term "regulation" refers to the increase or decrease of a specific reaction or parameter determined by any of a variety of well-known or commonly used tests, some of which are shown in this article.
[0291] A cell-mediated response is an immune response that does not involve antibodies but involves the activation of macrophages, natural killer cells (NK), antigen-specific cytotoxic T lymphocytes, and the release of various cytokines in response to the antigen. Cell-mediated immunity is often used to refer to certain Th cell activation, Tc cell activation, and T cell-mediated responses. Cell-mediated immunity may be particularly important in the response to viral infections.
[0292] For example, the induction of antigen-specific CD8 positive T lymphocytes can be measured using an ELISPOT assay; the stimulation of CD4 positive T lymphocytes can be measured using a proliferation assay. Anti-influenza virus hemagglutinin antibody titers can be quantified using an enzyme-linked immunosorbent assay (ELISA); the isotype of antigen-specific or cross-reactive antibodies can also be determined using anti-isotype antibodies (e.g., anti-IgG, IgA, IgE, or IgM). Methods and techniques for performing such assays are well known in the art.
[0293] The presence or level of cytokines can also be quantified. For example, T helper cell responses (Th1 / Th2) are characterized by measuring IFN- and IL-4 secreting cells using ELISA (e.g., BD Biosciences OptEIA kit). Peripheral blood mononuclear cells (PBMC) or splenocytes obtained from a subject can be cultured and the supernatant analyzed. T lymphocytes can also be quantitatively analyzed by fluorescence activated cell sorting (FACS) using marker-specific fluorescent markers and methods known in the art.
[0294] Microneutralization assays can also be performed to characterize the immune response of a subject, for example, see the method published by Rowe et al. in 1973. Virus neutralization titers can be quantified in a variety of ways, including: counting the number of lytic plaques after crystallographic fixation / staining of cells (plaque analysis); microscopic observation of cell lysis in vitro; and 2) enzyme-linked immunosorbent assay and spectrophotometric detection of influenza virus.
[0295] As used herein, the term "epitope" refers to the structural portion of an antigen to which an antibody specifically binds.
[0296] For example, an immune response induced by the administration of wild-type influenza virus hemagglutinin protein or VLP or mutant influenza virus hemagglutinin protein or VLP produced from plants can be observed in Balb / C mice. Serum samples of blood collected from animals can be analyzed by enzyme-linked immunosorbent assay (ELISA) for H3-specific total IgG and IgA antibodies. In the serum of each treatment group, mice immunized with wild-type influenza virus hemagglutinin or mutant influenza virus hemagglutinin protein produced from plants may show hemagglutinin-specific IgG antibody titers.
[0297] Plant Expression
[0298] The constructs of the present invention can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, microinjection, electroporation, etc. For reviews of these techniques, see, for example, Weissbach and Weissbach, Methods in Plant Molecular Biology, Academy Press, New York VIII, pp. 421-463 (1988); Geierson and Corey, Plant Molecular Biology, 2nd ed. (1988); and Miki and Iyer, Plants Basic knowledge of gene transferPlant Metabolism, 2nd ed., DT. DT. Dennis, DH Turpin, DD Lefebrvre, DB Layzell (eds), Addison Wesly, Langmans Ltd. London, pp. 561-579 (1997). Other methods include direct DNA uptake, use of liposomes, electroporation (e.g., using protoplasts), microinjection, microparticles or whiskers, and vacuum infiltration. See, for example, Bilang et al. (1991, Gene 100: 247-250), Scheid et al. (1991, Mol. Gen. Genet. 228: 104-112), Guerche et al. (1987, Plant Science 52: 111-116), Neuhause et al. (1987, Theor. Appl Genet. 75: 30-36), Klein et al. (2987, Nature 327: 70-73); Freeman et al. (1984, Plant Cell Physiol. 29: 1353), Howell et al. (1985, Science 227: 1229-1231), DeBlock et al. (1989, Plant Physiology 91: 694-701), Methods in Plant Molecular Biology (Weissbach and Weissbach, eds., Academic Press Inc., 1988), Methods in Plant Molecular Biology (Schuler and Zielinski, eds., Academic Press Inc., 1989), WO 92 / 09696, WO 94 / 00583, EP 331083, EP 175966, Liu and Lomonossoff (2002, J Virol Meth, 105: 343-348), EP 290395; WO8706614; U.S. Patents 4,945,050; 5,036,006; and 5,100,792, U.S. Patent Application 08 / 438,666 filed May 10, 1995, and 07 / 951,715 filed September 25, 1992 (all of which are incorporated herein by reference).
[0299] Transient expression methods can be used to express the constructs of the present invention (see D'Aoust et al., 2009, Methods in Molecular Biology, Vol. 483, pp. 41-50; Liu and Lomonossoff, 2002, Journal of Virological Methods, 105: 343-348; these documents are incorporated herein by reference). Alternatively, vacuum-based transient expression methods as described in Kapila et al. (1997, Plant Sci. 122, 101-108; the document is incorporated herein by reference) or WO 00 / 063400, WO 00 / 037663 (these documents are incorporated herein by reference) can be used. These methods may include, for example, but are not limited to agricultural inoculation or agricultural infiltration, syringe infiltration methods, but, as described above, other transient methods may also be used. By agricultural inoculation, agricultural infiltration or syringe infiltration, the Agrobacterium mixture including the desired nucleic acid enters the intercellular space of the tissue, such as the leaves, aerial parts (including stems, leaves and flowers) of the plant, other parts of the plant (stems, roots, flowers) or the whole plant. After passing through the epidermis, Agrobacterium infects and transfers t-DNA copies into the cell. The t-DNA is episomally transcribed and the mRNA is translated, which results in the production of the protein of interest in the infected cell, however, the delivery of the t-DNA into the nucleus is transient.
[0300] Transgenic plants, plant cells or seeds containing the gene constructs of the present invention are also considered to be part of the present invention and can be used as platform plants suitable for transient protein expression as described herein. Methods for regenerating whole plants from plant cells are also known in the art (see, for example, Guerineau and Mullineaux (1993, "Plant Transformation and Expression Vectors", included in "Oxford Plant Molecular Biology Labfax (Croy RRD edition), BIOS Science Press, pages 121-148). In general, the transformed plant cells are cultured in an appropriate culture medium, which may contain a selective agent (e.g., an antibiotic), wherein a selective marker is used to facilitate identification of the transformed plant cells. Once callus tissue is formed, the formation of buds can be promoted by using appropriate plant hormones in a known manner, and the buds are transferred to a rooting medium to regenerate the plant. These plants can then be used to form repeated generations from seeds or using vegetative propagation techniques. Transgenic plants can also be produced without the use of tissue culture. The stable transformation and regeneration methods of these organisms are established in the art and are known to those skilled in the art. Available techniques can be found in the works of Vasil et al. (Plant Cell Culture and Somatic Cell Genetics, Laboratory Procedures and Applications, Academic Press, 1984) and Weissbach and Weissbach (Methods in Plant Molecular Biology, Academic Press, 1989). The method of obtaining transformed and regenerated plants is not critical to the present invention.
[0301] If preparation is carried out transformation or co-transformation to plant, plant part or plant cell by two or more nucleic acid constructs, then this nucleic acid construct can be introduced into Agrobacterium in a single transfection event, so that nucleic acid is gathered and bacterial cell is transfected.Or, construct can be introduced successively.In this case, as described above, the first construct is introduced into Agrobacterium, and cell is grown under the selective condition (for example, under the condition of having antibiotic) that only single transformed bacterium can grow.After this first selection step, as described above, the second nucleic acid construct is introduced into Agrobacterium, and cell is grown under the dual selective condition that only double transformed bacterium can grow.Then, can use the bacterium of double transformation to transform plant, plant part or plant cell as described herein, or can carry out further transformation step to include the 3rd nucleic acid construct.
[0302] Alternatively, if a plant, plant part or plant cell is to be transformed or co-transformed by two or more nucleic acid constructs, the nucleic acid constructs can be introduced into the plant by co-infiltration of a mixture of Agrobacterium cells with the plant, plant part or plant cell, wherein each Agrobacterium cell can contain one or more constructs to be introduced into the plant. In order to change the relative expression level of the nucleotide sequence of interest in the construct in the plant, plant part or plant cell, the concentration of each Agrobacterium population containing the desired construct can be varied during the infiltration step.
[0303] Table 3: Serial numbers and serial descriptions
[0304]
[0305]
[0306]
[0307] The present invention will be further illustrated in the following examples.
[0308] Example 1: Influenza virus hemagglutinin construct
[0309] Influenza virus hemagglutinin constructs were generated using techniques known in the art. For example, wild-type H3 A-Switzerland / 9715293 / 13HA, N382A A / Switzerland / 9715293 / 13 H3 hemagglutinin and CysTM A-Switzerland-9715293-13 were cloned as described below. Other H3 hemagglutinin mutants were obtained using similar techniques, and hemagglutinin sequence primers, templates and products are illustrated in Example 3 (producing influenza virus hemagglutinin and VLPs in plants) and Table 4.
[0310] Table 4 below summarizes wild-type and mutant hemagglutinin proteins, primers, templates and products. For H3 influenza virus constructs except A / Switzerland / 9715293 / 13 hemagglutinin proteins cloned into the 1190 cloning vector without M2, the cloning vector used is integrated with the M2 influenza virus ion channel gene, which is controlled by the alfalfa plastocyanin promoter and terminator in addition to being controlled by the 2X35S promoter / expression cassette based on CPMV 160+CPMV 3'UTR / NOS. Plasmid 3556 (SEQ ID NO: 66; Figure 5A ) was digested with SacII and StuI restriction endonucleases and used in fusion reactions.
[0311] Modification of H3 hemagglutinin
[0312] 2X35S / CPMV 160 / PDISP-HA0 H3 A-Switzerland-9715293-13 / NOS (Construct No.2801)
[0313] The following PCR-based method was used to clone the sequence encoding the mature HA0 of influenza virus hemagglutinin from H3 A / Switzerland / 9715293 / 13 fused with the alfalfa PDI secretion signal peptide into the 2X35S / CPMV160 / NOS expression system. The PDISP-H1A / Switzerland / 9715293 / 13 gene sequence (SEQ ID NO: 9) was used as a template, and the fragment containing the PDISP-H3 A / Switzerland / 9715293 / 13 coding sequence was amplified using primers IF-CPMV (f15′UTR)_SpPDI.c (SEQ ID NO: 15) and IF-H3A-Ala.r (SEQ ID NO: 17). The PCR product was cloned into the 2X35S / CPMV 160 / NOS expression system using the fusion cloning system (Clontech, Mountain View, California, USA). The construct 1190 ( was digested with SacII and StuI restriction enzymes. Figure 5B ), and a linearized plasmid was used for the fusion assembly reaction. Construct 1190 is a receptor plasmid for "fusion" cloning of genes of interest in an expression cassette based on 2X35S / CPMV 160 / NOS. It also combines a gene construct for co-expressing the TBSV P19 silencing suppressor under the action of the alfalfa plastocyanin gene promoter and terminator. The backbone is the pCAMBIA binary plasmid, and the t-DNA border sequence from left to right is shown in sequence number 62. The resulting construct was numbered 2801 (sequence number 103). The amino acid sequence of mature HA0 from A / Switzerland / 9715293 / 13 fused with the alfalfa PDI secretion signal peptide (PDISP) is shown in sequence number 10. Figure 8J A schematic diagram of plasmid 2801 is shown in FIG.
[0314] 2X35S / CPMV 160 / PDISP-HA0 H3 A-Switzerland-9715293-13(N382A) / NOS(Build Body No. 3023)
[0315] The following PCR-based method was used to clone the sequence encoding the mature HA0 of influenza virus hemagglutinin from A / Switzerland / 9715293 / 13 (N382A) fused to the alfalfa PDI secretion signal peptide into the 2X35S / CPMV 160 / NOS expression system. In the first round of PCR, the PDISP-H3 A / Switzerland / 9715293 / 13 gene sequence (SEQ ID NO: 9) was used as a template, and primers IF-CPMV (f15′UTR)_SpPDI.c (SEQ ID NO: 15) and H3_Swi (N382A).r (SEQ ID NO: 50) were used to amplify a fragment of PDISP-H3 A / Switzerland / 9715293 / 13 containing the mutated N382A amino acid. Using the PDISP-H3 A / Switzerland / 9715293 / 13 gene sequence (SEQ ID NO: 9) as a template, H3_Swi(N382A).c (SEQ ID NO: 51) and IF-H3A-Ala.r (SEQ ID NO: 17) were used to amplify the second fragment containing the N382A mutation and the remainder of H3 A / Switzerland / 9715293 / 13. The PCR products of the two amplifications were then mixed and used as a template for a second round of amplification using IF-CPMV(f15′UTR)_SpPDI.c (SEQ ID NO: 15) and IF-H3A-Ala.r (SEQ ID NO: 17) as primers. The final PCR product was cloned into the 2X35S / CPMV 160 / NOS expression system using the fusion cloning system (Clontech, Mountain View, California, USA). Construct 1190( was digested with SacII and StuI restriction enzymes. Figure 5B ), and a linearized plasmid was used for the fusion assembly reaction. Construct 1190 is a recipient plasmid for "fusion" cloning of genes of interest in an expression cassette based on 2X35S / CPMV 160 / NOS. It also combines a gene construct for co-expressing the TBSV P19 silencing suppressor under the action of the alfalfa plastocyanin gene promoter and terminator. The backbone is the pCAMBIA binary plasmid, and the t-DNA border sequence from left to right is shown in sequence number 62. The resulting construct was numbered 3023 (sequence number 104). The amino acid sequence of the mutated PDISP-H3 A-Switzerland-9715293-13 (N382A) is shown in sequence number 82. Figure 4C A schematic diagram of plasmid 3023 is shown in FIG.
[0316] 2X35S / CPMV 160 / PDISP-HA0 H3 A-Switzerland-9715293-13(CvsTM) / NOS(Build Body No. 2811)
[0317] The following PCR-based method was used to clone the sequence encoding the mature HA0 of influenza virus hemagglutinin from A / Switzerland / 9715293 / 13 (CysTM) fused to the alfalfa PDI secretion signal peptide into the 2X35S / CPMV 160 / NOS expression system. In the first round of PCR, the PDISP-H3 A / Switzerland / 9715293 / 13 gene sequence (SEQ ID NO: 9) was used as a template, and primers IF-CPMV (f15′UTR)_SpPDI.c (SEQ ID NO: 15) and H3_Swi_SLVLL.r (SEQ ID NO: 18) were used to amplify a fragment of PDISP-H3 A / Switzerland / 9715293 / 13 containing a mutated CysTM amino acid. Using the PDISP-H3 A / Switzerland / 9715293 / 13 gene sequence (sequence number 9) as a template, H3_Swi_SLVLL.c (sequence number 19) and IF-H3A-Ala.r (sequence number 17) were used to amplify the second fragment containing the CysTm mutation and the remainder of H3 A / Switzerland / 9715293 / 13. The PCR products of the two amplifications were then mixed and used as a template for the second round of amplification using IF-CPMV (f15′UTR)_SpPDI.c (sequence number 15) and IF-H3A-Ala.r (sequence number 17) as primers. The final PCR product was cloned into the 2X35S / CPMV 160 / NOS expression system using the fusion cloning system (Clontech, Mountain View, California, USA). Construct 1190 ( Figure 5B ), and a linearized plasmid is used for the fusion assembly reaction. Construct 1190 is a receptor plasmid for "fusion" cloning of genes of interest in an expression cassette based on 2X35S / CPMV 160 / NOS. It also combines a gene construct for co-expressing the TBSV P19 silencing suppressor under the action of the alfalfa plastocyanin gene promoter and terminator. The backbone is the pCAMBIA binary plasmid, and the t-DNA border sequence from left to right is shown in sequence number 62. The resulting construct is numbered 2811 (sequence number 105). The amino acid sequence of the mutated PDISP-H3A-Switzerland-9715293-13 (CysTM) is shown in sequence number 49. Figure 8K A schematic diagram of plasmid 2811 is shown in FIG.
[0318] Example 2: Method
[0319] Agrobacterium tumefaciens transfection
[0320] Agrobacterium tumefaciens strain AGL1 was transfected with wild-type influenza virus hemagglutinin or mutant influenza virus hemagglutinin expression vectors by electroporation using the method described by D'Aoust et al. (Plant Biotech. J. 6: 930-40). Transfected Agrobacterium was grown in YEB medium supplemented with 10 mM 2-(N-morpholino)ethanesulfonic acid (MES), 20 μM acetosyringone, 50 μg / ml kanamycin and 25 μg / ml carbenicillin, pH 5.6, until OD600 reached between 0.6 and 1.6. Agrobacterium suspension was centrifuged and resuspended in infiltration medium (10 mM MgCl2 and 10 mM MES, pH 5.6) before use.
[0321] Plant biomass, inoculum preparation and agroinfiltration
[0322] Benth's Nicotiana plants were grown from seeds in flats filled with commercial peat moss substrate. The plants were grown in a greenhouse under a 16 / 8 photoperiod and a temperature of 25°C day / 20°C night. Three weeks after sowing, individual plantlets were selected, transplanted into pots, and grown in a greenhouse under the same environmental conditions for another three weeks.
[0323] Agrobacterium transfected with each wild-type influenza virus hemagglutinin or mutant influenza virus hemagglutinin expression vector was grown in YEB medium with 10 mmol 2-(N-morpholino)ethanesulfonic acid (MES), 20 microns of acetosyringone, 50 μg / ml kanamycin and 25 μg / ml carbenicillin, pH 5.6. Until they reached an OD600 between 0.6 and 1.6. The Agrobacterium suspension was centrifuged before use and resuspended in infiltration medium (10 mmol MgCl2 and 10 mmol MES, pH 5.6) and stored overnight at 4°C. On the day of infiltration, the culture batch was diluted to 2.5 times the culture volume and kept warm before use. In an airtight stainless steel tank with a vacuum degree of 20-40 Torr, the whole Nicotiana benthamiana was inverted in the bacterial suspension for 2 minutes. The plant was returned to the greenhouse and cultivated for 6 or 9 days until harvest.
[0324] Leaf harvest and total protein extraction
[0325] Protein was extracted from fresh biomass cut into approximately 1 cm2 pieces by overnight enzyme extraction at room temperature using an orbital shaker. The slurry was then filtered through a large pore nylon filter to remove undigested coarse plant tissue.
[0326] In order to obtain " full process output ", slurry is centrifuged to remove protoplasts and intracellular pollutants. Make supernatant clarify by depth filtration.Then the clarified part is loaded on the cation exchange column, adopts the progressive elution step that improves sodium chloride concentration gradually.The VLP of purifying is concentrated with TFF, and its diafiltration is carried out with formulation buffer, and it is passed through filter.By the protein content of the VLP of BCA test analysis purification, and by hemagglutination assay analysis activity.By comparing the protein output of the new construct with the protein output of the natural construct (or CysTM for H3 strain) used as a control, relative output is obtained.
[0327] In order to obtain "post-density gradient yield", the slurry is centrifuged to remove protoplasts and intracellular contaminants. The supernatant is further centrifuged to remove additional debris. The supernatant is filtered and clarified with a glass fiber filter. The clarified part is then loaded on a discontinuous iodixanol density gradient device. Separation density gradient centrifugation is performed as follows: 38 ml test tubes containing a discontinuous iodixanol density gradient are prepared in Tris buffer (35%, 30%, 25%, 20%, 15%, 10% and 5% continuous layers) and covered with a clarified extract. The gradient solution is centrifuged for 2 hours (4°C) at 120000g. After centrifugation, the initial 5 ml collected from bottom to top are discarded, and the next 5 ml are collected for protein content analysis (BCA), activity measurement (hemagglutination test) and HAO band intensity measurement (densitometry) on simplified SDS-PAGE. Relative yield is obtained by comparing the HAO band intensity of the new construct with the HAO band intensity of the natural construct (or CysTM for H3 strain) used as a control.
[0328] Hemagglutination test
[0329] The hemagglutination test is based on the method described by Nayak and Reichl (2004). In brief, a serial double dilution of the test sample (100 microliters) is performed in a V-bottom 96-well microtiter plate containing 100 microliters of PBS, leaving 100 microliters of the diluted sample in each well. 100 microliters of 0.5% guinea pig erythrocyte suspension (Bio Link Inc., New York, USA) is added to each well, and the well plate is incubated for 2 hours at room temperature. The reciprocal of the highest dilution indicating complete hemagglutination is recorded as hemagglutinin activity. At the same time, the recombinant hemagglutinin standard (A / Vietnam / 1203 / 2004 H5N1) (Protein Science Corporation, Meriden, Connecticut, USA) is diluted in PBS and used as a control on each well plate.
[0330] Protein analysis and immunoblotting
[0331] Immunoblotting was performed by first incubation with primary mAb diluted 1 / 500 in 2% skim milk in 0.1% TBS-Tween 20. Peroxidase-conjugated goat anti-mouse antibody (Jackson Immunoresearch, cat#115-035-146) diluted 1 / 10000 was used as secondary antibody, and chemiluminescent detection was performed in 2% skim milk in 0.1% TBS-Tween 20 immunoreactive complex using luminol as substrate (Roche Diagnostics Corporation). Horseradish peroxidase-enzyme conjugation of human IgG antibodies was performed using the Activated Peroxidase Conjugation Kit (Pierce, Rockford, IL).
[0332] Example 3: Production of influenza virus hemagglutinin protein in plants
[0333] Modification of H3 hemagglutinin I
[0334] Influenza virus hemagglutinin constructs were generated using techniques known in the art (see Example 1). Table 4 below summarizes wild-type and mutant hemagglutinin proteins, primers, templates, and products. The sequences used are listed in Example 4 and the sequence listing.
[0335] N382A A / Switzerland / 9715293 / 13 mutant H3
[0336] N382A A / Switzerland / 9715293 / 13 mutant H3 (construct number 3023) was constructed by mutating the asparagine at position 382 of wild-type / Switzerland / 9715293 / 13 H3 to alanine. Figure 2 As shown, purified extracts from N. benthamiana plants infiltrated with construct number 3023 exhibited approximately 30% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with wild type A / Switzerland / 9715293 / 13 H3 (construct number 2801).
[0337] L384V A / Switzerland / 9715293 / 13 mutant H3
[0338] L384V A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3034) was constructed by mutating the leucine at position 384 of wild-type / Switzerland / 9715293 / 13 H3 to valine. Figure 2As shown, purified extracts from N. benthamiana plants infiltrated with construct number 3034 exhibited approximately 100% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with wild type A / Switzerland / 9715293 / 13 H3 (construct number 2801).
[0339] F392D A / Switzerland / 9715293 / 13 mutant H3
[0340] The F392D A / Switzerland / 9715293 / 13 mutant H3 was constructed by mutating the phenylalanine residue at position 392 of wild-type A / Switzerland / 9715293 / 13 H3 to aspartic acid (construct number 3045). Figure 2 As shown, purified extracts from N. benthamiana plants infiltrated with construct number 3045 exhibited approximately 40% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with wild type A / Switzerland / 9715293 / 13 H3 (construct number 2801).
[0341] L431M A / Switzerland / 9715293 / 13 mutant H3
[0342] The L431M A / Switzerland / 9715293 / 13 mutant H3 was constructed by mutating the leucine residue at position 431 of the wild-type A / Switzerland / 9715293 / 13 H3 to methionine (construct number 3022). Figure 2 As shown, purified extracts from N. benthamiana plants infiltrated with construct number 3022 exhibited approximately 70% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with wild type A / Switzerland / 9715293 / 13 H3 (construct number 2811).
[0343] One or more mutations described herein specifically increase the production and VLP production of influenza virus hemagglutinin protein in plants. It has been observed that mutations at other positions significantly reduce the accumulation amount or VLP production of influenza virus hemagglutinin protein in plant cells, or have no significant effect on it.
[0344] It was also observed that the increase in hemagglutination titers achieved with influenza virus hemagglutinin proteins comprising one or more mutations described herein was specific to H3 influenza virus hemagglutinin. Similar enhancements were not observed in plants infiltrated with constructs encoding mutant influenza virus hemagglutinins derived from non-H3 strains.
[0345] For example, F393D A / Indonesia / 5 / 2005 mutant H5 (Construct No. 3680) was constructed by mutating the phenylalanine residue at position 393 of wild-type A / Indonesia / 5 / 2005 H5 to aspartic acid. Figure 3 As shown, purified extracts from N. benthamiana plants infiltrated with construct number 3680 exhibited approximately 98% reduction in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with wild type A / Indonesia / 5 / 2005 H5 (construct number 2295).
[0346] Similarly, purified extracts of N. benthamiana plants infiltrated with F392D A / Egypt / N04915 / 2014 mutant H5 (Construct No. 3690) showed approximately 99% reduction in hemagglutination titer compared to extracts of N. benthamiana plants infiltrated with wild-type A / E04915 / 2014 H5 (Construct No. 3645) (see Figure 3 , Table 7).
[0347] Modification of H3 hemagglutinin II
[0348] CysTM A / Switzerland / 9715293 / 13 mutant H3
[0349] CysTM A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 2811) was constructed by replacing the "CFLLC" sequence at positions 524-528 (SEQ ID NO. 99) of wild-type A / Switzerland / 9715293 / 13 H3 with "SLVLL" (SEQ ID NO. 98). Fig. 6A As shown, purified extracts from N. benthamiana plants infiltrated with construct number 2811 exhibited approximately 60% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with wild type A / Switzerland / 9715293 / 13 H3 (construct number 2801).
[0350] CysTM A / Pennsylvania / 09 / 2015 mutant H3
[0351] CysTM A / Pennsylvania / 09 / 2015 mutant H3 (Construct No. 3313) was constructed by replacing the "CFLLC" sequence at positions 524-528 (SEQ ID NO. 99) of wild-type A / Pennsylvania / 09 / 2015 H3 with "SLVLL" (SEQ ID NO. 98). Figure 7CAs shown, purified extracts of N. benthamiana plants infiltrated with Construct No. 3313 exhibited approximately 100% increase in hemagglutination titer compared to extracts of N. benthamiana plants infiltrated with wild-type A / Pennsylvania / 09 / 2015H3 (Construct No. 3312).
[0352] N382A+CysTM A / Switzerland / 9715293 / 13 mutant H3
[0353] N382A+CysTM A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3063) was constructed by mutating the asparagine at position 382 of wild-type A / Switzerland / 9715293 / 13 H3 to alanine and replacing the "CFLLC" sequence at positions 524-528 (SEQ ID NO. 99) with "SLVLL" (SEQ ID NO. 98). Fig. 7A As shown, purified extracts from N. benthamiana plants infiltrated with construct No. 3063 exhibited approximately 160% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with wild-type A / Switzerland / 9715293 / 13 H3 (construct No. 2801). Figure 7B As further shown, N. benthamiana infiltrated with construct No. 3063 exhibited approximately 30% increase in VLP production following iodixanol gradient purification compared to plants infiltrated with CysTM A / Switzerland / 9715293 / 13 mutant H3 (construct No. 2811).
[0354] N382A+CysTM A / Pennsylvania / 09 / 2015 mutant H3
[0355] N382A+CysTM A / Pennsylvania / 09 / 2015 mutant H3 (Construct No. 3314) was constructed by mutating the asparagine at position 382 of wild-type A / Pennsylvania / 09 / 2015 H3 to alanine and replacing the "CFLLC" series at positions 524-528 (SEQ ID NO. 99) with "SLVLL" (SEQ ID NO. 98). Figure 7C As shown, purified extracts from N. benthamiana plants infiltrated with Construct No. 3314 exhibited approximately 300% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with wild-type A / Pennsylvania / 09 / 2015H3 (Construct No. 3312).
[0356] L384V+CysTM A / Switzerland / 9715293 / 13 mutant H3
[0357] L384V+CysTM A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3074) was constructed by mutating the leucine at position 384 of wild-type A / Switzerland / 9715293 / 13 H3 to valine and replacing the "CFLLC" sequence at positions 524-528 (SEQ ID NO. 99) with "SLVLL" (SEQ ID NO. 98). Figure 7C As shown, purified extracts from N. benthamiana plants infiltrated with construct No. 3074 showed an approximately 380% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with wild-type A / Switzerland / 9715293 / 13 H3 (construct No. 2801). Figure 7B As further shown, N. benthamiana infiltrated with construct No. 3074 exhibited approximately 50% increase in VLP production after sucrose gradient purification compared to plants infiltrated with CysTM A / Switzerland / 9715293 / 13 mutant H3 (construct No. 2811).
[0358] L384V+CysTM A / Pennsylvania / 09 / 2015 mutant H3
[0359] L384V+CysTM A / Pennsylvania / 09 / 2015 mutant H3 (Construct No. 3315) was constructed by mutating the leucine at position 384 of wild-type A / Pennsylvania / 09 / 2015 H3 to valine and replacing the "CFLLC" series at positions 524-528 (SEQ ID NO. 99) with "SLVLL" (SEQ ID NO. 98). Figure 7C As shown, purified extracts of N. benthamiana plants infiltrated with Construct No. 3315 exhibited approximately 380% increase in hemagglutination titer compared to extracts of N. benthamiana plants infiltrated with wild-type A / Pennsylvania / 09 / 2015H3 (Construct No. 3312).
[0360] F392D+Cys TM A / Switzerland / 9715293 / 13 mutant H3
[0361] F392D+CysTM A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3085) was constructed by mutating the phenylalanine at position 392 of wild-type A / Switzerland / 9715293 / 13 H3 to aspartic acid and replacing the "CFLLC" sequence at positions 524-528 (SEQ ID NO. 99) with "SLVLL" (SEQ ID NO. 98). Fig. 7A As shown, purified extracts from N. benthamiana plants infiltrated with construct number 3085 exhibited approximately 170% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with wild type A / Switzerland / 9715293 / 13 H3 (construct number 2801).
[0362] L431M+CysTM A / Switzerland / 9715293 / 13 mutant H3
[0363] L431M+CysTM A / Switzerland / 9715293 / 13 mutant H3 (Construct No. 3062) was constructed by mutating the leucine at position 431 of wild-type A / Switzerland / 9715293 / 13 H3 to methionine and replacing the "CFLLC" sequence at positions 524-528 (SEQ ID NO. 99) with "SLVLL" (SEQ ID NO. 98). Fig. 7A As shown, purified extracts from N. benthamiana plants infiltrated with construct number 3062 exhibited approximately 150% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with wild type A / Switzerland / 9715293 / 13 H3 (construct number 2801).
[0364] N382A+L384V+CysTM A / Hong Kong / 4801 / 14 mutant H3
[0365] N382A+L384V+CysTM A / Hong Kong / 4801 / 14 mutant H3 (Construct No. 3375) was constructed by mutating the asparagine at position 382 of wild-type A / Hong Kong / 4801 / 14 to an alanine residue, mutating the leucine at position 384 to a valine residue, and replacing the "CFLLC" series at positions 524-528 (SEQ ID NO. 99) with "SLVLL" (SEQ ID NO. 98). Fig. 7EAs shown, purified extracts from N. benthamiana plants infiltrated with Construct No. 3375 exhibited approximately 300% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with CysTM A / Hong Kong / 4801 / 14 mutant H3 (Construct No. 3341).
[0366] N382A+L384V+CysTM A / Minnesota / 40 / 15 mutant H3
[0367] N382A+L384V+CysTM A / Minnesota / 40 / 15 mutant H3 (Construct No. 3915) was constructed by mutating the asparagine at position 382 of wild-type A / Minnesota / 40 / 15 to an alanine residue, mutating the leucine at position 384 to a valine residue, and replacing the "CFLLC" series at positions 524-528 (SEQ ID NO. 99) with "SLVLL" (SEQ ID NO. 98). Fig. 7E As shown, purified extracts from N. benthamiana plants infiltrated with Construct No. 3915 exhibited approximately 400% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with CysTM A / Minnesota / 40 / 15 mutant H3 (Construct No. 3914).
[0368] N382A+L384V+CysTM A / S.Australia / 1 / 16 mutant H3
[0369] N382A+L384V+CysTM A / S.Australia / 1 / 16 mutant H3 (Construct No. 3925) was constructed by mutating the asparagine at position 382 of wild-type A / S.Australia / 1 / 16 to an alanine residue, mutating the leucine at position 384 to a valine residue, and replacing the "CFLLC" series at positions 524-528 (SEQ ID NO. 99) with "SLVLL" (SEQ ID NO. 98). Fig.7D and 7E As shown, purified extracts from N. benthamiana plants infiltrated with construct No. 3925 exhibited approximately 400% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with CysTM A / S. Australia / 1 / 16 mutant H3 (construct No. 3924).
[0370] N382A+L384V+CysTM A / Bangkok / 3007 / 15 mutant H3
[0371] N382A+L384V+CysTM A / Bangkok / 3007 / 15 mutant H3 (Construct No. 3905) was constructed by mutating the asparagine at position 382 of wild-type A / Bangkok / 3007 / 15 to an alanine residue, mutating the leucine at position 384 to a valine residue, and replacing the "CFLLC" series at positions 524-528 (SEQ ID NO. 99) with "SLVLL" (SEQ ID NO. 98). Fig. 7E As shown, purified extracts from N. benthamiana plants infiltrated with Construct No. 3905 exhibited approximately 400% increase in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with CysTM A / Bangkok / 3007 / 15 mutant H3 (Construct No. 3904).
[0372] One or more mutations described herein specifically increase the production and VLP production of influenza virus hemagglutinin protein in plants. It has been observed that mutations at other positions significantly reduce the accumulation amount or VLP production of influenza virus hemagglutinin protein in plant cells, or have no significant effect on it.
[0373] It was also observed that the increase in hemagglutination titers achieved with influenza virus hemagglutinin proteins comprising one or more mutations described herein was specific to H3 influenza virus hemagglutinin. Similar enhancements were not observed in plants infiltrated with constructs encoding mutant influenza virus hemagglutinins derived from non-H3 strains.
[0374] For example, F393D A / Indonesia / 5 / 2005 mutant H5 (Construct No. 3680) was constructed by mutating the phenylalanine residue at position 393 of wild-type A / Indonesia / 5 / 2005 H5 to aspartic acid. Figure 3 As shown, purified extracts from N. benthamiana plants infiltrated with construct number 3680 exhibited approximately 98% reduction in hemagglutination titer compared to extracts from N. benthamiana plants infiltrated with wild type A / Indonesia / 5 / 2005 H5 (construct number 2295).
[0375] Similarly, purified extracts of N. benthamiana plants infiltrated with F392D A / Egypt / N04915 / 2014 mutant H5 (Construct No. 3690) showed approximately 99% reduction in hemagglutination titer compared to extracts of N. benthamiana plants infiltrated with wild-type A / E04915 / 2014 H5 (Construct No. 3690) (see Figure 3 ).
[0376]
[0377]
[0378] Example 3: Hemagglutination titer, post-density gradient yield, and overall process yield
[0379] Tables 5 and 6A summarize the measured hemagglutination titers. The hemagglutination titers were measured as described in Example 2. The relative hemagglutination titers were obtained by comparing the hemagglutination titers of the mutant or modified hemagglutinin proteins with the hemagglutination titers of the wild-type hemagglutinin (Table 5A) or the hemagglutination titers of the Cys™ mutant hemagglutinin proteins (Table 6A).
[0380] Tables A 5B and C5B summarize the measured post-density gradient yields. The post-density gradient yields were measured as described in Example 2. The relative yields were obtained by comparing the HAO band intensity of the mutant or modified hemagglutinin protein with the HAO band intensity of the wild-type hemagglutinin (Table 5B) or the HAO band intensity of the cysteine mutant hemagglutinin protein (Table 6B).
[0381] Table 6C summarizes the measured overall yields. Overall yields were obtained as described in Example 2. Relative yields were obtained by comparing the protein yields of mutant or modified hemagglutinin proteins with the protein yields of wild-type hemagglutinin or the protein yields of CysTM mutant hemagglutinin proteins (Table 6C).
[0382]
[0383]
[0384] Example 4: Sequence
[0385] The following sequences were used (see Table 4):
[0386]
[0387]
[0388]
[0389]
[0390]
[0391]
[0392]
[0393]
[0394]
[0395]
[0396]
[0397]
[0398]
[0399]
[0400]
[0401]
[0402]
[0403]
[0404]
[0405]
[0406]
[0407]
[0408]
[0409]
[0410]
[0411]
[0412] All cited documents are incorporated herein by reference.
[0413] The invention has been described with reference to one or more embodiments. However, it will be apparent to those skilled in the art that various changes and modifications may be made without departing from the scope of the invention as defined in the appended claims.
Claims
1. A modified H3 influenza virus hemagglutinin (HA) protein comprising the amino acid sequence of a wild-type H3 influenza virus hemagglutinin (HA) protein and comprising at least one amino acid substitution, wherein the at least one amino acid substitution consists of an amino acid substitution corresponding to the following positions: i) position 382 of the reference sequence SEQ ID NO:92; ii) position 384 of the reference sequence SEQ ID NO:92; iii) positions 382 and 384 of the reference sequence SEQ ID NO:92; iv) positions 382, 384 and 392 of the reference sequence SEQ ID NO:92; v) positions 382, 384 and 431 of the reference sequence SEQ ID NO:92; in: The amino acid substitution corresponding to position 382 of the reference sequence SEQ ID NO:92 is an alanine substitution; The amino acid substitution corresponding to position 384 of the reference sequence SEQ ID NO:92 is a valine substitution; The amino acid substitution corresponding to position 392 of the reference sequence SEQ ID NO:92 is an aspartic acid substitution; and The amino acid substitution corresponding to position 431 of the reference sequence SEQ ID NO:92 is a methionine substitution.
2. A nucleic acid encoding the modified H3 influenza virus hemagglutinin (HA) protein as claimed in claim 1.
3. A virus-like particle (VLP), comprising the modified H3 influenza virus hemagglutinin (HA) protein as claimed in claim 1.
4. A method for producing influenza virus-like particles (VLPs) in a plant, plant part or plant cell, the method comprising: a) introducing the nucleic acid according to claim 2 into the plant, plant part or plant cell; as well as b) cultivating the plant, plant part or plant cell under conditions allowing expression of the influenza virus hemagglutinin protein encoded by the nucleic acid, thereby producing the VLP.
5. The method of claim 4, wherein step a) further comprises introducing a second nucleic acid encoding a proton channel protein; and step b) further comprises cultivating the plant, plant part or plant cell under conditions allowing expression of the proton channel protein encoded by the second nucleic acid. The method according to claim 5 , wherein the proton channel protein is an influenza A virus M2 subtype protein.
7. The method according to any one of claims 4 to 6, wherein the method further comprises the step c) of harvesting the plant, plant part or plant cell and purifying the VLP.
8. A method for producing influenza virus-like particles (VLPs) in a plant, plant part or plant cell, the method comprising: a) providing a plant, plant part or plant cell comprising the nucleic acid according to claim 2; as well as b) cultivating the plant, plant part or plant cell under conditions allowing expression of the hemagglutinin protein encoded by the nucleic acid, thereby producing VLPs.
9. method according to claim 8, wherein the described plant, plant part or plant cell of step a) also comprises a second nucleic acid that encodes a proton channel protein; and wherein step b) also comprises cultivating the described plant, plant part or plant cell under the condition that allows the described proton channel protein encoded by the second nucleic acid to be expressed.
10. The method according to claim 9, wherein the proton channel protein is an influenza A virus M2 subtype protein.
11. The method according to any one of claims 8 to 10, wherein the method further comprises the step c) of harvesting the plant, plant part or plant cell and purifying the VLP.
12. A VLP produced by the method of any one of claims 4 to 11.
13. The VLP of claim 12, further comprising one or more lipids derived from the plant, plant part or plant cell, plant-specific N-glycans, modified N-glycans, or a combination thereof.
14. A composition for inducing an immune response, comprising an effective dose of the VLP according to any one of claims 3, 12 or 13, and a pharmaceutically acceptable carrier.
15. The composition of claim 14, wherein the pharmaceutically acceptable carrier is an adjuvant, a vehicle or an excipient.
16. Use of the VLP of any one of claims 3, 12 or 13 in the manufacture of a medicament for inducing immunity to influenza infection in a subject.
17. The use according to claim 16, wherein the VLP is formulated for oral, intranasal, intramuscular, intraperitoneal, intravenous or subcutaneous administration to the subject.
18. A method for increasing the production of influenza virus-like particles (VLPs) in a plant, plant part or plant cell, comprising: a) introducing the nucleic acid of claim 2 into the plant, plant part or plant cell; or providing the plant, plant part or plant cell comprising the nucleic acid of claim 2; and b) cultivating the plant, plant part or plant cell under conditions allowing expression of the hemagglutinin protein encoded by the nucleic acid, thereby producing the VLPs at a higher yield compared to a plant, plant part or plant cell expressing an unmodified influenza virus hemagglutinin protein.
19. The method according to claim 18, wherein the method further comprises the step c) of harvesting the plant, plant part or plant cell and purifying the VLP.
